Schizophrenia: A systematic review of the disease state, current therapeutics and their molecular mechanisms of action

Current Medicinal Chemistry

Volumn 18, Issue 9, 2011, Pages 1380-1404

  Shin, J K ^a   Malone, D T ^a   Crosby, I T ^a   Capuano, B ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Current therapeutics; Dopamine; Schizophrenia; Serotonin

Indexed keywords

2 AMINO 4 (4 FLUOROPHENYL) 5 [1 [4 (4 FLUOROPHENYL) 4 OXOBUTYL] 3 PYRROLIDINYL]THIAZOLE; 3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; ARIPIPRAZOLE; BENZODIAZEPINE; BUTYROPHENONE DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; KETANSERIN; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE DERIVATIVE; PLACEBO; PRUVANSERIN; QUETIAPINE; RISPERIDONE; RITANSERIN; SEROTONIN; SEROTONIN 2A ANTAGONIST; SEROTONIN RECEPTOR; SONEPIPRAZOLE; THIOXANTHINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLINANSERIN; ZIPRASIDONE;

AGITATION; AGRANULOCYTOSIS; AKATHISIA; ANXIETY; ARTICLE; ASTHENIA; BRAIN DISEASE; COGNITIVE DEFECT; CONCENTRATION RESPONSE; CONSTIPATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC TEST; DIARRHEA; DISEASE CLASSIFICATION; DIZZINESS; DOPAMINE RECEPTOR BLOCKING; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RESEARCH; DRUG WITHDRAWAL; DYSPEPSIA; ENVIRONMENTAL FACTOR; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; GENETIC PREDISPOSITION; GENETIC RISK; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; HYPOTENSION; INSOMNIA; INTERNATIONAL CLASSIFICATION OF DISEASES; MOLECULAR BIOLOGY; NAUSEA; NEGATIVE SYNDROME; NEUROLEPTIC MALIGNANT SYNDROME; NEUROMODULATION; NONHUMAN; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; POSITIVE SYNDROME; PROTEIN LOCALIZATION; PSYCHOSIS; QT PROLONGATION; RHINITIS; SCHIZOPHRENIA; SEDATION; SEROTONINERGIC NERVE CELL; SEROTONINERGIC SYSTEM; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; TARDIVE DYSKINESIA; WEIGHT CHANGE; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; BRAIN; DOPAMINE ANTAGONISTS; HUMANS; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS;

EID: 79952780420     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711795029546     Document Type: Article

References (415)

1. Laborit, H.; Huguenard, P.; Alluaume, R. A new vegetative stabilizer; 4560 R.P. Presse Med., 1952, 60(10), 206-208.
2. Harwood, P.D.; Jerstad, A.C.; Swanson, L.E. The efficacy of phenothazine for the removal of ascarids and nodular worms from swine. J. Parasitol., 1938, 24(Supplement), 16-17.
3. Charpentier, P.; Gailliot, P.; Jacob, R.; Gaudechon, J.; Buisson, P. Substituted 10-(dimethylaminopropyl)phenothiazines. Compt. rend., 1952, 235, 59-60.
4. Courvoisier, S. Pharmacodynamic properties of chlorpromazine in relation to its use in psychiatry. Encephale, 1956, 45(4), 1248-1257.
5. Delay, J.; Deniker, P. Neuroleptic effects of chlorpromazine in therapeutics of neuropsychiatry. J. Clin. Exp. Psychopathol., 1955, 16(2), 104-112.
6. Elkes, J.; Elkes, C. Effect of chlorpromazine on the behavior of chronically overactive psychotic patients. Br. Med. J., 1954, 2(4887), 560-565.
7. Winkelman, N.W., Jr. Chlorpromazine in the treatment of neuropsychiatric disorders. J. Am. Med. Assoc., 1954, 155, 18-21.
8. Kemali, D. Insulin therapy in psychiatry. Acta Neurol., 1968, 23(2), 356-381.
9. Masiak, M.; Perzynski, J.; Bednarski, M.; Czernikiewicz, A.; Welcz, H.; Wysocka, A. Insulin coma therapy in the treatment of early schizophrenia. Mater. Med. Pol., 1989, 21(1), 60-62. (Pubitemid 20094894)
10. Freeman, W. Frontal lobotomy in early schizophrenia. Long follow-up in 415 cases. Br. J. Psychiat., 1971, 119(553), 621-624.
11. Banen, D.M. Improvement, three years after lobotomy. Mil. Surg., 1953, 113(1), 31-35.
12. Buck, C.W.; Carscallen, H.B.; Hobbs, G.E. Lobotomy in schizophrenic patients a summary of published studies. Treat. Serv. Bull., 1951, 6(8), 399-404.
13. Wan, F.E.; Chang, T.H. Psychosurgery; report of thirty-three cases. Chin. Med. J., 1950, 68(9-10), 273-280.
14. Hoch, P. Treatment of schizophrenia with prolonged narcosis. Psychiat. Quart., 1935, 9(3), 386-391.
15. Ezhkov, A.A. Butyrylperazine (Randolectil) in the treatment of mental patients. Tr. Mosk. Nauch.-Issled. Inst. Psikhiat., 1967, 49, 592-599.
16. th ed.; American Psychiatric Association: 1994.
17. ICD-10: The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines, World Health Organization: 1992.
18. Kinney, D.K.; Matthysse, S. Genetic transmission of schizophrenia. Annu. Rev. Med., 1978, 29, 459-473.
19. Kety, S.S. Neurochemical and genetic bases of psychopathology: Current status. Behav. Genet., 1982, 12(1), 93-100. (Pubitemid 12109312)
20. Sham, P.C.; MacLean, C.J.; Kendler, K.S. A typological model of schizophrenia based on age at onset, sex and familial morbidity. Acta Psychiat. Scand., 1994, 89(2), 135-141. (Pubitemid 24047680)
21. Hafner, H.; van der Heiden, W.; Behrens, S.; Gattaz, W.F.; Hambrecht, M.; Loffler, W.; Maurer, K.; Munk-Jorgensen, P.; Nowotny, B.; Riecher-Rossler, A.; Stein, A. Causes and consequences of the gender difference in age at onset of schizophrenia. Schizophr. Bull., 1998, 24(1), 99-113. (Pubitemid 28128492)
22. Faraone, S.V.; Chen, W.J.; Goldstein, J.M.; Tsuang, M.T. Gender differences in age at onset of schizophrenia. Brit. J. Psychiat., 1994, 164(5), 625-629. (Pubitemid 24161260)
23. Kraepelin, E. Psychiatrie: Ein Lehrbuch fuer Studierende und Aerzte, 8 ed.; Verlag: Leipzig, 1909.
24. Gottesman, I.I. Schizophrenia Genesis: The Origins of Madness, W.H.Freeman & Co Ltd.: New York, 1991.
25. Kendler, K.S.; Diehl, S.R. The genetics of schizophrenia: A current, geneticepidemiologic perspective. Schizophr. Bull., 1993, 19(2), 261-285. (Pubitemid 23183148)
26. Tsuang, M.T.; Stone, W.S.; Faraone, S.V. Genes, environment and schizophrenia. Br. J. Psychiat. Suppl., 2001, 40, s18-24.
27. Kety, S.S. The significance of genetic factors in the etiology of schizophrenia: Results from the national study of adoptees in Denmark. J. Psychiatr. Res., 1987, 21(4), 423-429. (Pubitemid 18010254)
28. Tienari, P. Interaction between genetic vulnerability and family environment: The Finnish adoptive family study of schizophrenia. Acta Psychiat. Scand., 1991, 84(5), 460-465.
29. Wender, P.H.; Rosenthal, D.; Kety, S.S.; Schulsinger, F.; Welner, J. Crossfostering. A research strategy for clarifying the role of genetic and experiential factors in the etiology of schizophrenia. Arch. Gen. Psychiatry, 1974, 30(1), 121-128.
30. Ban, T.A. Neuropsychopharmacology: The interface between genes and psychiatric nosology. In Pharmacogenetics of Psychotropic Drugs, Cambridge University Press: Cambridge, 2002; pp 36-56.
31. Merikangas, K.R.; Avenevoli, S. Implications of genetic epidemiology for the prevention of substance use disorders. Addict. Behav., 2000, 25(6), 807-820.
32. Stober, G.; Meyer, J.; Nanda, I.; Wienker, T.F.; Saar, K.; Knapp, M.; Jatzke, S.; Schmid, M.; Lesch, K.P.; Beckmann, H. Linkage and family-based association study of schizophrenia and the synapsin III locus that maps to chromosome 22q13. Am. J. Med. Genet., 2000, 96(3), 392-397.
33. Hoeffer, A.; Pollin, W. Schizophrenia in the NAS-NRC panel of 15,909 veteran twin pairs. Arch. Gen. Psychiatry, 1970, 23(5), 469-477.
34. Koskenvuo, M.; Langinvainio, H.; Kaprio, J.; Lonnqvist, J.; Tienari, P. Psychiatric hospitalization in twins. Acta Genet. Med. Gemellol., 1984, 33(2), 321-332. (Pubitemid 15126099)
35. Johnstone, E.C.; Frith, C.D.; Lang, F.H.; Owens, D.G. Determinants of the extremes of outcome in schizophrenia. Br. J. Psychiat., 1995, 167(5), 604-609. (Pubitemid 26197769)
36. Day, R.; Nielsen, J.A.; Korten, A.; Ernberg, G.; Dube, K.C.; Gebhart, J.; Jablensky, A.; Leon, C.; Marsella, A.; Olatawura, M. Stressful life events preceding the acute onset of schizophrenia: A cross-national study from the World Health Organization. Cult. Med. Psychiat., 1987, 11(2), 123-205.
37. Rosenberg Stanley, D.; Lu, W.; Mueser Kim, T.; Jankowski Mary, K.; Cournos, F. Correlates of adverse childhood events among adults with schizophrenia spectrum disorders. Psychiatr. Serv., 2007, 58(2), 245-253. (Pubitemid 46340470)
38. Schenkel Lindsay, S.; Spaulding William, D.; DiLillo, D.; Silverstein Steven, M. Histories of childhood maltreatment in schizophrenia: Relationships with premorbid functioning, symptomatology, and cognitive deficits. Schizophr. Res., 2005, 76(2-3), 273-286. (Pubitemid 40804773)
39. Tienari, P.; Wynne, L.C.; Moring, J.; Lahti, I.; Naarala, M.; Sorri, A.; Wahlberg, K.E.; Saarento, O.; Seitamaa, M.; Kaleva, M. The Finnish adoptive family study of schizophrenia. Implications for family research. Br. J. Psychiat. Suppl., 1994, (23), 20-26. (Pubitemid 24141699)
40. Brown, G.W.; Birley, J.L.; Wing, J.K. Influence of family life on the course of schizophrenic disorders: A replication. Br. J. Psychiat., 1972, 121(562), 241-258.
41. Hollingshead, A.B.; Redlich, F.C. Schizophrenia and social structure. Am. J. Psychiat., 1954, 110(9), 695-701.
42. Harvey, C.A.; Pantelis, C.; Taylor, J.; McCabe, P.J.; Lefevre, K.; Campbell, P.G.; Hirsch, S.R. The Camden schizophrenia surveys. II. High prevalence of schizophrenia in an inner London borough and its relationship to sociodemographic factors. Br. J. Psychiat., 1996, 168(4), 418-426.
43. Turner, R.J.; Wagenfeld, M.O. Occupational mobility and schizophrenia: An assessment of the social causation and social selection hypotheses. Am. Sociol. Rev., 1967, 32(1), 104-113.
44. Kohn, M.L. The interaction of social class and other factors in the etiology of schizophrenia. Am. J. Psychiatry, 1976, 133(2), 177-180.
45. Mednick, S.A.; Machon, R.A.; Huttunen, M.O.; Bonett, D. Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch. Gen. Psychiatry, 1988, 45(2), 189-192. (Pubitemid 18052851)
46. Baron, M.; Gruen, R. Risk factors in schizophrenia. Season of birth and family history. Br. J. Psychiat., 1988, 152, 460-465.
47. Torrey, E.F.; Miller, J.; Rawlings, R.; Yolken, R.H. Seasonality of births in schizophrenia and bipolar disorder: A review of the literature. Schizophr. Res., 1997, 28(1), 1-38. (Pubitemid 27522788)
48. Cannon, T.D. Abnormalities of brain structure and function in schizophrenia: Implications for aetiology and pathophysiology. Ann. Med., 1996, 28(6), 533-539. (Pubitemid 27019551)
49. Rifkin, L.; Lewis, S.; Jones, P.; Toone, B.; Murray, R. Low birth weight and schizophrenia. Br. J. Psychiat., 1994, 165(3), 357-362. (Pubitemid 24274154)
50. Susser, E.; Neugebauer, R.; Hoek, H.W.; Brown, A.S.; Lin, S.; Labovitz, D.; Gorman, J.M. Schizophrenia after prenatal famine. Further evidence. Arch. Gen. Psychiatry, 1996, 53(1), 25-31.
51. Jacobi, W.; Winkler, H. Encephalographische Studien an chronisch Schizophrenen. Arch. Psychiatr. Nervenkr., 1927, 81, 299-332.
52. Henn, F.A.; Braus, D.F. Structural neuroimaging in schizophrenia. An integrative view of neuromorphology. Eur. Arch. Psychiatry Clin. Neurosci., 1999, 249 Suppl 4, 48-56.
53. McCarley, R.W.; Wible, C.G.; Frumin, M.; Hirayasu, Y.; Levitt, J.J.; Fischer, I.A.; Shenton, M.E. MRI anatomy of schizophrenia. Biol. Psychiatry, 1999, 45(9), 1099-1119. (Pubitemid 29236551)
54. Suddath, R.L.; Christison, G.W.; Torrey, E.F.; Casanova, M.F.; Weinberger, D.R. Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia. N. Engl. J. Med., 1990, 322(12), 789-794. (Pubitemid 20094141)
55. Weinberger, D.R.; Torrey, E.F.; Neophytides, A.N.; Wyatt, R.J. Lateral cerebral ventricular enlargement in chronic schizophrenia. Arch. Gen. Psychiatry, 1979, 36(7), 735-739. (Pubitemid 10102536)
56. Wolkin, A.; Rusinek, H.; Vaid, G.; Arena, L.; Lafargue, T.; Sanfilipo, M.; Loneragan, C.; Lautin, A.; Rotrosen, J. Structural magnetic resonance image averaging in schizophrenia. Am. J. Psychiatry, 1998, 155(8), 1064-1073. (Pubitemid 28357732)
57. Andreasen, N.C.; Olsen, S.A.; Dennert, J.W.; Smith, M.R. Ventricular enlargement in schizophrenia: Relationship to positive and negative symptoms. Am. J. Psychiatry, 1982, 139(3), 297-302. (Pubitemid 12180179)
58. Benes, F.M.; Kwok, E.W.; Vincent, S.L.; Todtenkopf, M.S. A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. Biol. Psychiatry, 1998, 44(2), 88-97. (Pubitemid 28305527)
59. Breier, A.; Buchanan, R.W.; Elkashef, A.; Munson, R.C.; Kirkpatrick, B.; Gellad, F. Brain morphology and schizophrenia. A magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures. Arch. Gen. Psychiatry, 1992, 49(12), 921-926.
60. Lawrie, S.M.; Abukmeil, S.S. Brain abnormality in schizophrenia. A systematic and quantitative review of volumetric magnetic resonance imaging studies. Br. J. Psychiat., 1998, 172, 110-120. (Pubitemid 28097708)
61. Nelson, M.D.; Saykin, A.J.; Flashman, L.A.; Riordan, H.J. Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: A meta-analytic study. Arch. Gen. Psychiatry, 1998, 55(5), 433-440. (Pubitemid 28237277)
62. Anderson Jane, E.; Wible Cynthia, G.; McCarley Robert, W.; Jakab, M.; Kasai, K.; Shenton Martha, E. An MRI study of temporal lobe abnormalities and negative symptoms in chronic schizophrenia. Schizophr. Res., 2002, 58(2-3), 123-134. (Pubitemid 35284504)
63. Barta, P.E.; Pearlson, G.D.; Powers, R.E.; Richards, S.S.; Tune, L.E. Auditory hallucinations and smaller superior temporal gyral volume in schizophrenia. Am. J. Psychiatry, 1990, 147(11), 1457-1462. (Pubitemid 20365432)
64. Shenton, M.E.; Kikinis, R.; Jolesz, F.A.; Pollak, S.D.; LeMay, M.; Wible, C.G.; Hokama, H.; Martin, J.; Metcalf, D.; Coleman, M. Abnormalities of the left temporal lobe and thought disorder in schizophrenia. A quantitative magnetic resonance imaging study. N. Engl. J. Med., 1992, 327(9), 604-612.
65. Andreasen, N.; Nasrallah, H.A.; Dunn, V.; Olson, S.C.; Grove, W.M.; Ehrhardt, J.C.; Coffman, J.A.; Crossett, J.H. Structural abnormalities in the frontal system in schizophrenia. A magnetic resonance imaging study. Arch. Gen. Psychiatry, 1986, 43(2), 136-144. (Pubitemid 16163532)
66. Ingvar, D.H.; Franzen, G. Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia. Acta Psychiat. Scand., 1974, 50(4), 425-462.
67. Buchsbaum, M.S.; DeLisi, L.E.; Holcomb, H.H.; Cappelletti, J.; King, A.C.; Johnson, J.; Hazlett, E.; Dowling-Zimmerman, S.; Post, R.M.; Morihisa, J.; Carpenter, W.; Cohen, R.; Pickar, D.; Weinberger, D.R.; Margolin, R.; Kessler, R.M.Anteroposterior gradients in cerebral glucose. Use in schizophrenia and affective disorders. Arch. Gen. Psychiatry, 1984, 41(12), 1159-1166. (Pubitemid 15215483)
68. Heckers, S. Neuropathology of schizophrenia: Cortex, thalamus, basal ganglia, and neurotransmitter-specific projection systems. Schizophr. Bull., 1997, 23(3), 403-421. (Pubitemid 27427982)
69. Knable, M.B.; Torrey, E.F.; Webster, M.J.; Bartko, J.J. Multivariate analysis of prefrontal cortical data from the Stanley Foundation Neuropathology Consortium. Brain Res. Bull., 2001, 55(5), 651-659. (Pubitemid 32888384)
70. Elkashef, A.M.; Egan, M.F.; Frank, J.A.; Hyde, T.M.; Lewis, B.K.; Wyatt, R.J. Basal ganglia iron in tardive dyskinesia: An MRI study. Biol. Psychiatry, 1994, 35(1), 16-21. (Pubitemid 24063269)
71. Beckmann, H.; Lauer, M. The human striatum in schizophrenia. II. Increased number of striatal neurons in schizophrenics. Psychiatry Res., 1997, 68(2-3), 99-109. (Pubitemid 27191433)
72. Lieberman, J.A.; Tollefson, G.D.; Charles, C.; Zipursky, R.; Sharma, T.; Kahn, R.S.; Keefe, R.S.E.; Green, A.I.; Gur, R.E.; McEvoy, J.; Perkins, D.; Hamer, R.M.; Gu, H.; Tohen, M. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch. Gen. Psychiatry, 2005, 62(4), 361-370. (Pubitemid 40471685)
73. Vita, A.; De Peri, L.; Silenzi, C.; Dieci, M. Brain morphology in first-episode schizophrenia: A meta-analysis of quantitative magnetic resonance imaging studies. Schizophr. Res., 2006, 82(1), 75-88. (Pubitemid 43202650)
74. Carlsson, A.; Waldeck, B. Fluorimetric method for the determination of 3- hydroxytyramine. Acta Physiol. Scand., 1958, 44, 293-298.
75. Bertler, A.; Rosengren, E. Occurrence and distribution of dopamine in brain and other tissues. Experientia, 1959, 15, 10-11.
76. Rashid, A.J.; So, C.H.; Kong, M.M.; Furtak, T.; El-Ghundi, M.; Cheng, R.; O'Dowd, B.F.; George, S.R. D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc. Natl. Acad. Sci. U.S.A., 2007, 104(2), 654-659. (Pubitemid 46123080)
77. Jarvie, K.R.; Caron, M.G. Heterogeneity of dopamine receptors. Adv. Neurol., 1993, 60, 325-333.
78. Giros, B.; Sokoloff, P.; Martres, M.P.; Riou, J.F.; Emorine, L.J.; Schwartz, J.C. Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature, 1989, 342(6252), 923-926. (Pubitemid 20021338)
79. Usiello, A.; Baik, J.-H.; Rougs-Pont, F.; Picetti, R.; Dierich, A.; LeMmeur, M.; Piazzas, P.V.; Bonrelli, E. Distinct functions of the two isoforms of dopamine D2 receptors. Nature, 2000, 408(6809), 199-203.
80. Wang, Y.; Xu, R.; Sasaoka, T.; Tonegawa, S.; Kung, M.-P.; Sankoorikal, E.- B. Dopamine D2 long receptor-deficient mice display alterations in striatumdependent functions. J. Neurosci., 2000, 20(22), 8305-8314.
81. Centonze, D.; Usiello, A.; Gubellini, P.; Pisani, A.; Borrelli, E.; Bernardi, G.; Calabresi, P. Dopamine D2 receptor-mediated inhibition of dopaminergic neurons in mice lacking D2L receptors. Neuropsychopharmacology, 2002, 27(5), 723-726. (Pubitemid 35335890)
82. Castro, S.W.; Strange, P.G. Differences in the ligand binding properties of the short and long versions of the D2 dopamine receptor. J. Neurochem., 1993, 60(1), 372-375. (Pubitemid 23006743)
83. Malmberg, A.; Jackson, D.M.; Eriksson, A.; Mohell, N. Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors. Mol. Pharmacol., 1993, 43(5), 749-754. (Pubitemid 23146274)
84. Snyder, L.A.; Roberts, J.L.; Sealfon, S.C. Alternative transcripts of the rat and human dopamine D3 receptor. Biochem. Bioph. Res. Co., 1991, 180(2), 1031-1035.
85. Fishburn, C.S.; Belleli, D.; David, C.; Carmon, S.; Fuchs, S. A novel short isoform of the D3 dopamine receptor generated by alternative splicing in the third cytoplasmic loop. J. Biol. Chem., 1993, 268(8), 5872-5878. (Pubitemid 23090921)
86. Seeman, P.; Van Tol, H.H.M. Dopamine receptor pharmacology. Trends Pharmacol. Sci., 1994, 15(7), 264-270. (Pubitemid 24210734)
87. Van Tol, H.H.M.; Wu, C.M.; Guan, H.C.; Ohara, K.; Bunzow, J.R.; Civelli, O.; Kennedy, J.; Seeman, P.; Niznik, H.B.; Jovanovic, V. Multiple dopamine D4 receptor variants in the human population. Nature, 1992, 358(6382), 149-152.
88. Kazmi, M.A.; Snyder, L.A.; Cypess, A.M.; Graber, S.G.; Sakmar, T.P. Selective reconstitution of human D4 dopamine receptor variants with gia subtypes. Biochemistry, 2000, 39(13), 3734-3744. (Pubitemid 30183855)
89. Bear, M.F.; Connors, B.W.; Paradiso, M.A. Neuroscience: Exploring the Brain, Williams & Wilkins: Baltimore, 1998.
90. Deutch, A.Y.; Goldstein, M.; Roth, R.H. The ascending projections of the dopaminergic neurons of the substantia nigra, zona reticulata: A combined retrograde tracer-immunohistochemical study. Neurosci. Lett, 1986, 71(3), 257-263. (Pubitemid 17168559)
91. Hokfelt, T.; Johansson, O.; Fuxe, K.; Goldstein, M.; Park, D. Immunohistochemical studies on the localization and distribution of monoamine neuron systems in the rat brain II. Tyrosine hydroxylase in the telencephalon. Med. Biol., 1977, 55(1), 21-40. (Pubitemid 8058534)
92. Hokfelt, T.; Johansson, O.; Fuxe, K.; Goldstein, M.; Park, D. Immunohistochemical studies on the localization and distribution of monoamine neuron systems in the rat brain. I. Tyrosine hydroxylase in the mes- And diencephalon. Med. Biol, 1976, 54(6), 427-453. (Pubitemid 8008686)
93. Iversen, S.D.; Iversen, L.L. Dopamine: 50 years in perspective. Trends Neurosci, 2007, 30(5), 188-193. (Pubitemid 46654233)
94. nd ed.; Cambridge University Press: New York, 2000.
95. Mogenson, G.J.; Jones, D.L.; Yim, C.Y. From motivation to action: Functional interface between the limbic system and the motor system. Prog. Neurobiol., 1980, 14(2-3), 69-97. (Pubitemid 10053405)
96. Ikemoto, S. Dopamine reward circuitry: Two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain Res. Rev., 2007, 56(1), 27-78. (Pubitemid 350110353)
97. Voorn, P.; Vanderschuren, L.J.M.J.; Groenewegen, H.J.; Robbins, T.W.; Pennartz, C.M.A. Putting a spin on the dorsal-ventral divide of the striatum. Trends Neurosci., 2004, 27(8), 468-474. (Pubitemid 38951039)
98. Rapport, M.M.; Green, A.A.; Page, I.H. Crystalline serotonin. Science, 1948, 108, 329-330.
99. Rapport, M.M.; Green, A.A.; Page, I.H. Partial purification of the vasoconstrictor in beef serum. J. Biol. Chem., 1948, 174, 735-741.
100. Rapport, M.M. Serum vasoconstrictor (serotonin). V. Presence of creatinine in the complex. Proposed structure of the vasoconstrictor principle. J. Biol. Chem., 1949, 180, 961-969.
101. Azmitia, E.C. Modern views on an ancient chemical: Serotonin effects on cell proliferation, maturation, and apoptosis. Brain Res. Bull., 2001, 56(5), 413-424. (Pubitemid 34031777)
102. McCarthy, G.; Blamire, A.M.; Puce, A.; Nobre, A.C.; Bloch, G.; Hyder, F.; Goldman-Rakic, P.; Shulman, R.G. Functional magnetic resonance imaging of human prefrontal cortex activation during a spatial working memory task. Proc. Natl. Acad. Sci. USA, 1994, 91(18), 8690-8694. (Pubitemid 24273730)
103. McCarthy, G.; Puce, A.; Constable, R.T.; Krystal, J.H.; Gore, J.C.; Goldman- Rakic, P. Activation of human prefrontal cortex during spatial and nonspatial working memory tasks measured by functional MRI. Cereb. Cortex, 1996, 6(4), 600-611. (Pubitemid 26278184)
104. Rogers, R.D.; Everitt, B.J.; Baldacchino, A.; Blackshaw, A.J.; Swainson, R.; Wynne, K.; Baker, N.B.; Hunter, J.; Carthy, T.; Booker, E.; London, M.; Deakin, J.F.W.; Sahakian, B.J.; Robbins, T.W. Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: Evidence for monoaminergic mechanisms. Neuropsychopharmacology, 1999, 20(4), 322-339. (Pubitemid 29099763)
105. Roth, B.L. Multiple serotonin receptors: Clinical and experimental aspects. Ann. Clin. Psychiatry, 1994, 6(2), 67-78. (Pubitemid 24312170)
106. Kroeze, W.K.; Roth, B.L. The molecular biology of serotonin receptors: Therapeutic implications for the interface of mood and psychosis. Biol. Psychiatry, 1998, 44(11), 1128-1142. (Pubitemid 28547147)
107. Davies, P.A.; Pistis, M.; Hanna, M.C.; Peters, J.A.; Lambert, J.J.; Hales, T.G.; Kirkness, E.F. The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature, 1999, 397(6717), 359-363.
108. Maricq, A.V.; Peterson, A.S.; Brake, A.J.; Myers, R.M.; Julius, D. Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel. Science, 1991, 254(5030), 432-437. (Pubitemid 21917361)
109. Hoyer, D.; Schoeffter, P. 5-HT receptors: Subtypes and second messengers. J. Receptor Res., 1991, 11(1-4), 197-214.
110. Julius, D. Molecular biology of serotonin receptors. Annu. Rev. Neurosci., 1991, 14, 335-360.
111. Bockaert, J.; Sebben, M.; Dumuis, A. Pharmacological characterization of 5- hydroxytryptamine4(5-HT4) receptors positively coupled to adenylate cyclase in adult guinea pig hippocampal membranes: Effect of substituted benzamide derivatives. Mol. Pharmacol., 1990, 37(3), 408-411. (Pubitemid 20115599)
112. Ruat, M.; Traiffort, E.; Arrang, J.M.; Tardivel-Lacombe, J.; Diaz, J.; Leurs, R.; Schwartz, J.C. A novel rat serotonin (5-HT6) receptor: Molecular cloning, localization and stimulation of cAMP accumulation. Biochem. Bioph. Res. Co., 1993, 193(1), 268-276. (Pubitemid 23199942)
113. Bard, J.A.; Zgombick, J.; Adham, N.; Vaysse, P.; Branchek, T.A.; Weinshank, R.L. Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. J. Biol. Chem., 1993, 268(31), 23422-23426. (Pubitemid 23328066)
114. Carson, M.J.; Thomas, E.A.; Danielson, P.E.; Sutcliffe, J.G. The 5HT5A serotonin receptor is expressed predominantly by astrocytes in which it inhibits cAMP accumulation: A mechanism for neuronal suppression of reactive astrocytes. Glia, 1996, 17(4), 317-326. (Pubitemid 26309424)
115. Noda, N.; Yasuda, S.; Okada, M.; Higashida, H.; Shimada, A.; Iwata, N.; Ozaki, N.; Nishikawa, K.; Shirasawa, S.; Uchida, M.; Aoki, S.; Wada, K. Recombinant human serotonin 5A receptors stably expressed in C6 glioma cells couple to multiple signal transduction pathways. J. Neurochem., 2003, 84(2), 222-232. (Pubitemid 36182264)
116. Noda, M.; Higashida, H.; Aoki, S.; Wada, K. Multiple signal transduction pathways mediated by 5-HT receptors. Mol. Neurobiol., 2004, 29(1), 31-39. (Pubitemid 39118077)
117. Baxter, G.; Kennett, G.; Blaney, F.; Backburn, T. 5-HT2 receptor subtypes: A family re-united. Trends Pharmacol. Sci., 1995, 16(3), 105-110.
118. Roth, B.L.; Berry, S.A.; Kroeze, W.K.; Willins, D.L.; Kristiansen, K. Serotonin 5-HT2A receptors: Molecular biology and mechanisms of regulation. Crit. Rev. Neurobiol., 1998, 12(4), 319-338. (Pubitemid 29073863)
119. Harrison, P.J.; Burnet, P.W. The 5-HT2A (serotonin2A) receptor gene in the aetiology, pathophysiology and pharmacotherapy of schizophrenia. J. Psychopharmacol., 1997, 11(1), 18-20. (Pubitemid 27146030)
120. Lopez-Gimenez, J.F.; Mengod, G.; Palacios, J.M.; Vilaro, M.T. Selective visualization of rat brain 5-HT2A receptors by autoradiography with [3H]MDL 100,907. N-S Arch. Pharmacol., 1997, 356(4), 446-454. (Pubitemid 27402083)
121. Pazos, A.; Cortes, R.; Palacios, J.M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res., 1985, 346(2), 231-249. (Pubitemid 16241112)
122. Pazos, A.; Probst, A.; Palacios, J.M. Serotonin receptors in the human brain. IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience, 1987, 21(1), 123-139. (Pubitemid 17076867)
123. Jakab, R.L.; Goldman-Rakic, P.S. 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: Possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc. Natl. Acad. Sci. USA, 1998, 95(2), 735-740.
124. Williams, G.V.; Rao, S.G.; Goldman-Rakic, P.S. The physiological role of 5- HT2A receptors in working memory. J. Neurosci., 2002, 22(7), 2843-2854. (Pubitemid 37465833)
125. Jacobs, B.L.; Azmitia, E.C. Structure and function of the brain serotonin system. Physiol. Rev., 1992, 72(1), 165-229.
126. Nedergaard, S.; Bolam, J.P.; Greenfield, S.A. Facilitation of a dendritic calcium conductance by 5-hydroxytryptamine in the substantia nigra. Nature, 1988, 333(6169), 174-177.
127. Olpe, H.R.; Koella, W.P. The response of striatal cells upon stimulation of the dorsal and median raphe nuclei. Brain Res., 1977, 122(2), 357-360. (Pubitemid 8039041)
128. Ashby, C.R., Jr.; Jiang, L.H.; Kasser, R.J.; Wang, R.Y. Electrophysiological characterization of 5-hydroxytryptamine2 receptors in the rat medial prefrontal cortex. J. Pharmacol. Exp. Ther., 1990, 252(1), 171-178. (Pubitemid 20067710)
129. Mantz, J.; Godbout, R.; Tassin, J.P.; Glowinski, J.; Thierry, A.M. Inhibition of spontaneous and evoked unit activity in the rat medial prefrontal cortex by mesencephalic raphe nuclei. Brain Res., 1990, 524(1), 22-30. (Pubitemid 20254691)
130. Horn, A.S.; Snyder, S.H. Chlorpromazine and dopamine: Conformational similarities that correlate with the antischizophrenic activity of phenothiazine drugs. Proc. Natl. Acad. Sci. U.S.A., 1971, 68(10), 2325-2328.
131. Matthysse, S. Antipsychotic drug actions. Clue to the neuropathology of schizophrenia. Fed. Proc., 1973, 32(2), 200-205.
132. Bowers, M.B., Jr. Central dopamine turnover in schizophrenic syndromes. Arch. Gen. Psychiatry, 1974, 31(1), 50-54.
133. Goldsmith, S.K.; Shapiro, R.M.; Joyce, J.N. Disrupted pattern of D2 dopamine receptors in the temporal lobe in schizophrenia. A postmortem study. Arch. Gen. Psychiatry, 1997, 54(7), 649-658. (Pubitemid 27306575)
134. Hietala, J.; Syvalahti, E.; Vuorio, K.; Nagren, K.; Lehikoinen, P.; Ruotsalainen, U.; Rakkolainen, V.; Lehtinen, V.; Wegelius, U. Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch. Gen. Psychiatry, 1994, 51(2), 116-123. (Pubitemid 24054313)
135. Tune, L.E.; Wong, D.F.; Pearlson, G.; Strauss, M.; Young, T.; Shaya, E.K.; Dannals, R.F.; Wilson, A.A.; Ravert, H.T.; Sapp, J. Dopamine D2 receptor density estimates in schizophrenia: A positron emission tomography study with 11C-N-methylspiperone. Psychiatry Res., 1993, 49(3), 219-237.
136. Wong, D.F.; Wagner, H.N., Jr.; Tune, L.E.; Dannals, R.F.; Pearlson, G.D.; Links, J.M.; Tamminga, C.A.; Broussolle, E.P.; Ravert, H.T.; Wilson, A.A.; Toung. J.K.T.; Malat, J.; Williams, J.A.; O'Tuama, L.A.; Snyder. S.H.; Kuhar, M.J.; Gjedde, A. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science, 1986, 234(4783), 1558-1563. (Pubitemid 17125279)
137. Angrist, B.; Lee, H.K.; Gershon, S. The antagonism of amphetamine-induced symptomatology by a neuroleptic. Am. J. Psychiat., 1974, 131(7), 817-819.
138. Snyder, S.H. Amphetamine psychosis. Model schizophrenia mediated by catechol amines. Am. J. Psychiat., 1973, 130(1), 61-67.
139. Griffiths, R.R.; Stitzer, M.; Corker, K.; Bigelow, G.; Liebson, I. Drugproduced changes in human social behavior: Facilitation by d-amphetamine. Pharmacol. Biochem. Be., 1977, 7(4), 365-372. (Pubitemid 8238457)
140. Angrist, B.M.; Gershon, S. The phenomenology of experimentally induced amphetamine psychosis-preliminary observations. Biol. Psychiatry, 1970, 2(2), 95-107.
141. Creese, I.; Burt, D.R.; Snyder, S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science, 1976, 192(4238), 481-483.
142. Seeman, P.; Lee, T.; Chau-Wong, M.; Wong, K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature, 1976, 261(5562), 717-719.
143. Farde, L.; Nordstrom, A.L.; Wiesel, F.A.; Pauli, S.; Halldin, C.; Sedvall, G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry, 1992, 49(7), 538-544.
144. Kapur, S. Receptor occupancy by antipsychotics- concepts and findings. In Neurotransmitter Receptors in Actions of Antipsychotic Medications, CRC Press LLC: Boca Raton, 2000; pp 163-176.
145. Nordstrom, A.L.; Farde, L.; Wiesel, F.A.; Forslund, K.; Pauli, S.; Halldin, C.; Uppfeldt, G. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients. Biol. Psychiatry, 1993, 33(4), 227-235. (Pubitemid 23091497)
146. Kapur, S.; Seeman, P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am. J. Psychiat., 2001, 158(3), 360-369. (Pubitemid 32205190)
147. Abi-Dargham, A.; Laruelle, M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: Insights from brain imaging studies. Eur. Psychiatry, 2005, 20(1), 15-27. (Pubitemid 40092387)
148. Pilowsky, L.S.; Costa, D.C.; Ell, P.J.; Murray, R.M.; Verhoeff, N.P.; Kerwin, R.W. Antipsychotic medication, D2 dopamine receptor blockade and clinical response: A 123I IBZM SPET (single photon emission tomography) study. Psychol. Med., 1993, 23(3), 791-797. (Pubitemid 23268097)
149. Meltzer, H.Y. Treatment of schizophrenia and spectrum disorders: Pharmacotherapy, psychosocial treatments, and neurotransmitter interactions. Biol. Psychiatry, 1999, 46(10), 1321-1327.
150. Meltzer, H.Y.; Matsubara, S.; Lee, J.C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther., 1989, 251(1), 238-246.
151. Schwartz, J.C.; Diaz, J.; Pilon, C.; Sokoloff, P. Possible implications of the dopamine D3 receptor in schizophrenia and in antipsychotic drug actions. Brain Res. Rev., 2000, 31(2/3), 277-287. (Pubitemid 30136182)
152. Seeman, P.; Tallerico, T.; Corbett, R.; Van Tol, H.H.M.; Kamboj, R.K. Role of dopamine D2, D4 and serotonin2A receptors in antipsychotic and anticataleptic action. J. Psychopharmacol., 1997, 11(1), 15-17. (Pubitemid 27146029)
153. Svensson, T.H. a-Adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2003, 27(7), 1145-1158. (Pubitemid 37464959)
154. Van Tol, H.H.M.; Bunzow, J.R.; Guan, H.C.; Sunahara, R.K.; Seeman, P.; Niznik, H.B.; Civelli, O. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature, 1991, 350(6319), 610-614. (Pubitemid 21912282)
155. Richtand, N.M.; Welge, J.A.; Logue, A.D.; Keck, P.E., Jr.; Strakowski, S.M.; McNamara, R.K. Dopamine and Serotonin Receptor Binding and Antipsychotic Efficacy. Neuropsychopharmacology, 2007, 32(8), 1715-1726. (Pubitemid 47076385)
156. Seeman, P.; Guan, H.C.; Van Tol, H.H.M. Dopamine D4 receptors elevated in schizophrenia. Nature, 1993, 365(6445), 441-445. (Pubitemid 23311038)
157. Murray, A.M.; Hyde, T.M.; Knable, M.B.; Herman, M.M.; Bigelow, L.B.; Carter, J.M.; Weinberger, D.R.; Kleinman, J.E. Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia. J. Neurosci., 1995, 15(3, Pt. 2), 2186-2191.
158. Sumiyoshi, T.; Stockmeier, C.A.; Overholser, J.C.; Thompson, P.A.; Meltzer, H.Y. Dopamine D4 receptors and effects of guanine nucleotides on [3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression. Brain Res., 1995, 681(1,2), 109-116.
159. Lahti, R.A.; Roberts, R.C.; Conley, R.R.; Cochrane, E.V.; Mutin, A.; Tamminga, C.A. D2-type dopamine receptors in postmortem human brain sections from normal and schizophrenic subjects. NeuroReport, 1996, 7(12), 1945-1948. (Pubitemid 26348199)
160. Reynolds, G.P.; Mason, S.L. Absence of detectable striatal dopamine D4 receptors in drug-treated schizophrenia. Eur. J. Pharmacol., 1995, 281(2), R5-R6.
161. Reynolds, G.P.; Mason, S.L. Are striatal dopamine D4 receptors increased in schizophrenia? J. Neurochem., 1994, 63(4), 1576-1577.
162. Lahti, R.A.; Roberts, R.C.; Cochrane, E.V.; Primus, R.J.; Gallager, D.W.; Conley, R.R.; Tamminga, C.A. Direct determination of dopamine D4 receptors in normal and schizophrenic postmortem brain tissue. A [3H]NGD- 94-1 study. Mol. Psychiatr., 1998, 3(6), 528-533.
163. Thurkauf, A.; Yuan, J.; Chen, X.; He, X.S.; Wasley, J.W.F.; Woodruff, K.H.; Meade, R.; Hoffman, D.C.; Donovan, H.; Jones-Hertzog, D.K. 2-Phenyl- 4(5)- [ [4-(pyrimidin-2- yl)piperazin-1-yl]methyl]imidazole. A Highly Selective
164. Tallman, J.F. NGD 94-1: A specific dopamine-4-receptor antagonist. Adv. Psychol., 1998, 42(Catecholamines), 490-492.
165. Jentsch, J.D.; Taylor, J.R.; Redmond, D.E., Jr.; Elsworth, J.D.; Youngren, K.D.; Roth, R.H. Dopamine D4 receptor antagonist reversal of subchronic phencyclidine-induced object retrieval/detour deficits in monkeys. Psychopharmacology, 1999, 142(1), 78-84. (Pubitemid 29196067)
166. Gazi, L.; Sommer, B.; Nozulak, J.; Schoeffter, P. NGD 94-1 as an agonist at human recombinant dopamine D4.4 receptors expressed in HEK293 cells. Eur. J. Pharmacol., 1999, 372(3), R9-R10. (Pubitemid 29255978)
167. Kulagowski, J.J.; Broughton, H.B.; Curtis, N.R.; Mawer, I.M.; Ridgill, M.P.; Baker, R.; Emms, F.; Freedman, S.B.; Marwood, R.; Patel, S.; Patel, S.; Ragan, C.I.; Leeson, P.D. 3- [ [4-(4-Chlorophenyl)piperazin-1-yl]methyl]- 1Hpyrrolo [ 2,3-b]pyridine: An antag-onist with high affinity and selectivity for the human dopamine D4 receptor. J. Med. Chem., 1996, 39(10), 1941-1942. (Pubitemid 26163243)
168. Bristow, L.J.; Kramer, M.S.; Kulagowski, J.; Patel, S.; Ragan, C.I.; Seabrook, G.R. Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist. Trends Pharmacol. Sci., 1997, 18(6), 186-188. (Pubitemid 27283645)
169. Kramer, M.S.; Last, B.; Getson, A.; Reines, S.A. the effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. Arch. Gen. Psychiatry, 1997, 54(6), 567-572. (Pubitemid 27258555)
170. Gazi, L.; Bobirnac, I.; Danzeisen, M.; Schupbach, E.; Bruinvels, A.T.; Geisse, S.; Sommer, B.; Hoyer, D.; Tricklebank, M.; Schoeffter, P. The agonist activities of the putative antipsychotic agents, L-745,870 and U- 101958 in HEK293 cells expressing the human dopamine D4.4 receptor. Br. J. Pharmacol., 1998, 124(5), 889-896. (Pubitemid 28312822)
171. Merchant, K.M.; Gill, G.S.; Harris, D.W.; Huff, R.M.; Eaton, M.J.; Lookingland, K.; Lutzke, B.S.; McCall, R.B.; Piercey, M.F.; Schreur, P.J.K.D.; Sethy, V.H.; Smith, M.W.; Svensson, K.A.; Tang, A.H.; Vonvoigtlander, P.F.; Tenbrink, R.E. Pharmacological characterization of U- 101387, a dopamine D4 receptor selective antagonist. J. Pharmacol. Exp. Ther., 1996, 279(3), 1392-1403. (Pubitemid 27166788)
172. TenBrink, R.E.; Bergh, C.L.; Duncan, J.N.; Harris, D.W.; Huff, R.M.; Lahti, R.A.; Lawson, C.F.; Lutzke, B.S.; Martin, I.J.; Rees, S.A.; Schlachter, S.K.; Sih, J.C.; Smith, M.W. (S)-(-)-4- [4- [2-(Isochroman-1-yl)ethyl]piperazin- 1- yl]benzenesulfonamide , a Selective Dopamine D4 Antagonist. J. Med. Chem., 1996, 39(13), 2435-2437. (Pubitemid 26199134)
173. Feldpausch, D.L.; Needham, L.M.; Stone, M.P.; Althaus, J.S.; Yamamoto, B.K.; Svensson, K.A.; Merchant, K.M. The role of dopamine D4 receptor in the induction of behavioral sensitization to amphetamine and accompanying biochemical and molecular adaptations. J. Pharmacol. Exp. Ther., 1998, 286(1), 497-508. (Pubitemid 28318026)
174. Meng, Z.-h.; Feldpaush, D.L.; Merchant, K.M. Clozapine and haloperidol block the induction of behavioral sensitization to amphetamine and associated genomic responses in rats. Mol. Brain Res., 1998, 61(1,2), 39-50. (Pubitemid 28511346)
175. Corrigan, M.H.; Gallen, C.C.; Bonura, M.L.; Merchant, K.M. Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: A placebocontrolled trial. Biol. Psychiatry, 2004, 55(5), 445-451. (Pubitemid 38338530)
176. Sanner, M.A.; Chappie, T.A.; Dunaiskis, A.R.; Fliri, A.F.; Desai, K.A.; Zorn, S.H.; Jackson, E.R.; Johnson, C.G.; Morrone, J.M.; Seymour, P.A.; Majchrzak, M.J.; Faraci, W.S.; Collins, J.L.; Duignan, D.B.; Di Prete, C.C.; Lee, J.S.; Trozzi, A. Synthesis, SAR and pharmacology of CP-293,019: A potent, selective dopamine D4 receptor antagonist. Bioorg. Med. Chem. Lett., 1998, 8(7), 725-730. (Pubitemid 28160029)
177. Mansbach, R.S.; Brooks, E.W.; Sanner, M.A.; Zorn, S.H. Selective dopamine D4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition. Psychopharmacology, 1998, 135(2), 194-200. (Pubitemid 28055503)
178. Geyer, M.A.; Ellenbroek, B. Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog. Neuro-Psychopharmacol. Biol. Psychiatry Mech. Atypicality Antipsychtic Drugs, 2003, 27(7), 1071-1079. (Pubitemid 37464953)
179. Zhang, K.; Tarazi, F.I.; Baldessarini, R.J. Role of dopamine D4 receptors in motor hyperactivity induced by neonatal 6-hydroxydopamine lesions in rats. Neuropsychopharmacology, 2001, 25(5), 624-632. (Pubitemid 32995944)
180. Tamminga, C.A.; Schaffer, M.H.; Smith, R.C.; Davis, J.M. Schizophrenic symptoms improve with apomorphine. Science, 1978, 200(4341), 567-568. (Pubitemid 8350342)
181. Clark, D.; Carlsson, A.; Hjorth, S.; Svensson, K.; Engel, J.; Sanchez, D. Is 3- PPP a potential antipsychotic agent? Evidence from animal behavioral studies. Eur. J. Pharmacol., 1982, 83(1-2), 131-134. (Pubitemid 12019394)
182. Lahti, A.C.; Weiler, M.A.; Corey, P.K.; Lahti, R.A.; Carlsson, A.; Tamminga, C.A. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in schizophrenia. Biol. Psychiatry, 1998, 43(1), 2-11. (Pubitemid 28059067)
183. Clark, D.; Carlsson, A.; Hjorth, S.; Engel, J.; Lindberg, P. The effect of the enantiomers of 3-PPP on conditioned avoidance responding in the rat. Psychopharmacology, 1983, 81(1), 14-17. (Pubitemid 13038254)
184. Gattaz, W.F.; Rost, W.; Hubner, C.K.; Bauer, K. Acute and subchronic effects of low-dose bromocriptine in haloperidol-treated schizophrenics. Biol. Psychiatry, 1989, 25(3), 247-255. (Pubitemid 19044250)
185. Hjorth, S.; Carlsson, A.; Clark, D.; Svensson, K.; Wikstroem, H.; Sanchez, D.; Lindberg, P.; Hacksell, U.; Arvidsson, L.E.; Johansson, A.; Nilsson, J.L. The search for selective dopaminergic autoreceptor agonists. J. Neural. Transm-Supp., 1983, 18(Basic Aspects Recept. Biochem.), 131-137.
186. Olbrich, R.; Schanz, H. An evaluation of the partial dopamine agonist terguride regarding positive symptoms reduction in schizophrenics. J. Neural. Transm-Gen., 1991, 84(3), 233-236.
187. Oshiro, Y.; Sato, S.; Kurahashi, N.; Tanaka, T.; Kikuchi, T.; Tottori, K.; Uwahodo, Y.; Nishi, T. Novel antipsychotic agents with dopamine autoreceptor agonist properties: Synthesis and pharmacology of 7- [4-(4- phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives. J. Med. Chem., 1998, 41(5), 658-667. (Pubitemid 28114874)
188. Svensson, K.; Ekman, A.; Piercey, M.F.; Hoffmann, W.E.; Lum, J.T.; Carlsson, A. Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study. N-S Arch. Pharmacol., 1991, 344(3), 263-274.
189. Kikuchi, T.; Tottori, K.; Uwahodo, Y.; Hirose, T.; Miwa, T.; Oshiro, Y.; Morita, S. 7-{4- [4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy}-3,4-dihydro- 2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J. Pharmacol. Exp. Ther., 1995, 274(1), 329-336.
190. Lawler, C.P.; Prioleau, C.; Lewis, M.M.; Mak, C.; Jiang, D.; Schetz, J.A.; Gonzalez, A.M.; Sibley, D.R.; Mailman, R.B. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology, 1999, 20(6), 612-627. (Pubitemid 29189265)
191. Semba, J.; Watanabe, A.; Kito, S.; Toru, M. Behavioral and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain. Neuropharmacology, 1995, 34(7), 785-791.
192. Jordan, S.; Koprivica, V.; Chen, R.; Tottori, K.; Kikuchi, T.; Altar, C.A. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur. J. Pharmacol., 2002, 441(3), 137-140. (Pubitemid 34626163)
193. Keltner Norman, L.; Johnson, V. Biological perspectives. Aripiprazole: A third generation of antipsychotics begins? Perspect. Psychiatr. Care, 2002, 38(4), 157-159. (Pubitemid 36120837)
194. Burris, K.D.; Molski, T.F.; Xu, C.; Ryan, E.; Tottori, K.; Kikuchi, T.; Yocca, F.D.; Molinoff, P.B. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther., 2002, 302(1), 381-389. (Pubitemid 34680462)
195. Kikuchi, T.; Tottori, K.; Uwahodo, Y.; Hirose, T.; Miwa, T.; Oshiro, Y.; Morita, S. Pharmacological effects of aripiprazole (OPC-14597), a novel antipsychotic drug. Shinkei Seishin Yakuri, 1995, 17(10), 719-727.
196. Yokoi, F.; Grunder, G.; Biziere, K.; Stephane, M.; Dogan, A.S.; Dannals, R.F.; Ravert, H.; Suri, A.; Bramer, S.; Wong, D.F. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): A study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology, 2002, 27(2), 248-259. (Pubitemid 34692591)
197. El-Sayeh, H.G.; Morganti, C. Aripiprazole for schizophrenia. Cochrane Database Syst. Rev., 2006, (2), CD004578.
198. Gaddum, J.H.; Hameed, K.A. Drugs which antagonize 5-hydroxytryptamine. Br. J. Pharm. Chemoth., 1954, 9, 240-248.
199. Woolley, D.W.; Shaw, E. A biochemical and pharmacological suggestion about certain mental disorders. Proc. Natl. Acad. Sci. U.S.A., 1954, 40, 228-231.
200. Glennon, R.A. Do classical hallucinogens act as 5-HT2 agonists or antagonists? Neuropsychopharmacology, 1990, 3(5-6), 509-517.
201. Crow, T.J.; Baker, H.F.; Cross, A.J.; Joseph, M.H.; Lofthouse, R.; Longden, A.; Owen, F.; Riley, G.J.; Glover, V.; Killpack, W.S. Monoamine mechanisms in chronic schizophrenia: Post-mortem neurochemical findings. Br. J. Psychiatry., 1979, 134(March), 249-256. (Pubitemid 9127859)
202. Arora, R.C.; Meltzer, H.Y. Serotonin2(5-HT2) receptor binding in the frontal cortex of schizophrenic patients. J. Neural. Transm-Gen., 1991, 85(1), 19-29.
203. Burnet, P.W.; Eastwood, S.L.; Harrison, P.J. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology, 1996, 15(5), 442-455. (Pubitemid 26389868)
204. Hashimoto, T.; Kitamura, N.; Kajimoto, Y.; Shirai, Y.; Shirakawa, O.; Mita, T.; Nishino, N.; Tanaka, C. Differential changes in serotonin 5-HT1A and 5- HT2 receptor binding in patients with chronic schizophrenia. Psychopharmacology, 1993, 112(1, Suppl.), S35-S39. (Pubitemid 23263248)
205. Mita, T.; Hanada, S.; Nishino, N.; Kuno, T.; Nakai, H.; Yamadori, T.; Mizoi, Y.; Tanaka, C. Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol. Psychiatry, 1986, 21(14), 1407-1414. (Pubitemid 17191380)
206. Gurevich, E.V.; Joyce, J.N. Alterations in the cortical serotonergic system in schizophrenia: A postmortem study. Biol. Psychiatry, 1997, 42(7), 529-545. (Pubitemid 27425471)
207. Hashimoto, T.; Nishino, N.; Nakai, H.; Tanaka, C. Increase in serotonin 5- HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci., 1991, 48(4), 355-363.
208. Assie, M.-B.; Cosi, C.; Koek, W. 5-HT1A receptor agonist properties of the antipsychotic, nemonapride: Comparison with bromerguride and clozapine. Eur. J. Pharmacol., 1997, 334(2/3), 141-147. (Pubitemid 27451982)
209. Newman-Tancredi, A.; Gavaudan, S.; Conte, C.; Chaput, C.; Touzard, M.; Verriele, L.; Audinot, V.; Millan, M.J. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: A [35S]GTPgS binding study. Eur. J. Pharmacol., 1998, 355(2/3), 245-256. (Pubitemid 28404707)
210. Shapiro, D.A.; Renock, S.; Arrington, E.; Chiodo, L.A.; Liu, L.-X.; Sibley, D.R.; Roth, B.L.; Mailman, R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology, 2003, 28(8), 1400-1411. (Pubitemid 41070874)
211. Arnt, J.; Skarsfeldt, T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology, 1998, 18(2), 63-101. (Pubitemid 28026679)
212. Bymaster, F.P.; Calligaro, D.O.; Falcone, J.F.; Marsh, R.D.; Moore, N.A.; Tye, N.C.; Seeman, P.; Wong, D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology, 1996, 14(2), 87-96. (Pubitemid 26053226)
213. Leysen, J.E.; Gommeren, W.; Eens, A.; De Chaffoy de Courcelles, D.; Stoof, J.C.; Jenssen, P.A.J. Biochemical profile of risperidone, a new antipsychotic. J. Pharmacol. Exp. Ther., 1988, 247(2), 661-670.
214. Farde, L.; Nordstrom, A.L.; Nyberg, S.; Halldin, C.; Sedvall, G. D1-, D2-, and 5-HT2-receptor occupancy in clozapine-treated patients. J. Clin. Psychiatry, 1994, 55 Suppl B, 67-69.
215. Nordstrom, A.L.; Farde, L.; Halldin, C. High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology, 1993, 110(3), 365-367. (Pubitemid 23051140)
216. Nordstrom, A.L.; Farde, L.; Nyberg, S.; Karlsson, P.; Halldin, C.; Sedvall, G. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: A PET study of schizophrenic patients. Am. J. Psychiat., 1995, 152(10), 1444-1449.
217. Lee, T.; Tang, S.W. Loxapine and clozapine decrease serotonin (S2) but do not elevate dopamine (D2) receptor numbers in the rat brain. Psychiatry Res., 1984, 12(4), 277-285. (Pubitemid 14028751)
218. Reynolds, G.P.; Garrett, N.J.; Rupniak, N.; Jenner, P.; Marsden, C.D. Chronic clozapine treatment of rats down-regulates cortical 5-HT2 receptors. Eur. J. Pharmacol., 1983, 89(3-4), 325-326. (Pubitemid 13095882)
219. Willins, D.L.; Berry, S.A.; Alsayegh, L.; Backstrom, J.R.; Sanders-Bush, E.; Friedman, L.; Roth, B.L. Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5- hydroxytryptamine-2A receptors in vitro and in vivo. Neuroscience, 1999, 91(2), 599-606. (Pubitemid 29193269)
220. Leysen, J.E.; Gommeren, W.; Van Gompel, P.; Wynants, J.; Janssen, P.F.M.; Laduron, P.M. Receptor-binding properties in vitro and in vivo of ritanserin, a very potent and long-acting serotonin-S2 antagonist. Mol. Pharmacol., 1985, 27(6), 600-611. (Pubitemid 15010691)
221. Colpaert, F.C.; Meert, T.F.; Niemegeers, C.J.E.; Janssen, P.A.J. Behavioral and 5-HT antagonist effects of ritanserin: A pure and selective antagonist of LSD discrimination in rat. Psychopharmacology, 1985, 86(1-2), 45-54. (Pubitemid 15075572)
222. Akhondzadeh, S.; Malek-Hosseini, M.; Ghoreishi, A.; Raznahan, M.; Rezazadeh, S.A. Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, 32(8), 1879-1883.
223. Wiesel, F.A.; Nordstrom, A.L.; Farde, L.; Eriksson, B. An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology (Berl), 1994, 114(1), 31-38. (Pubitemid 24150517)
224. Duinkerke, S.J.; Botter, P.A.; Jansen, A.A.; van Dongen, P.A.; van Haaften, A.J.; Boom, A.J.; van Laarhoven, J.H.; Busard, H.L. Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebocontrolled double-blind trial. Br. J. Psychiat., 1993, 163, 451-455. (Pubitemid 23297461)
225. Wiesel, F.A.; Nordstrom, A.L.; Farde, L.; Eriksson, B. An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology, 1994, 114(1), 31-38. (Pubitemid 24150517)
226. Den Boer, J.A.; Vahlne, J.O.; Post, P.; Heck, A.H.; Daubenton, F.; Olbrich, R. Ritanserin as add-on medication to neuroleptic therapy for patients with chronic or subchronic schizophrenia. Hum. Psychopharmacol., 2000, 15(3), 179-189. (Pubitemid 30258834)
227. Herndon, J.L.; Ismaiel, A.; Ingher, S.P.; Teitler, M.; Glennon, R.A. Ketanserin analogs: Structure-affinity relationships for 5-HT2 and 5-HT1C serotonin receptor binding. J. Med. Chem., 1992, 35(26), 4903-4910. (Pubitemid 23030927)
228. Leysen, J.E.; Niemegeers, C.J.E.; Van Nueten, J.M.; Laduron, P.M. [3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol. Pharmacol., 1982, 21(2), 301-314. (Pubitemid 12139828)
229. Cools, A.R.; Prinssen, E.; Ellenbroek, B.A. Interaction between aminergic systems in mesolimbic structures: The importance of 5-HT2, D2 and D1 receptors in the olfactory tubercle for the atypical profile of neuroleptics. Clin. Neuropharmacol., 1992, 15 Suppl 1 Pt A, 618A-619A.
230. Kehne, J.H.; Baron, B.M.; Carr, A.A.; Chaney, S.F.; Elands, J.; Feldman, D.J.; Frank, R.A.; van Giersbergen, P.L.; McCloskey, T.C.; Johnson, M.P.; McCarty, D.R.; Poirot, M.; Senyah, Y.; Siegel, B.W.; Widmaier, C. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J. Pharmacol. Exp. Ther., 1996, 277(2), 968-981.
231. Maurel-Remy, S.; Bervoets, K.; Millan, M.J. Blockade of phencyclidineinduced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors. Eur. J. Pharmacol., 1995, 280(2), R9-R11.
232. Sorensen, S.M.; Kehne, J.H.; Fadayel, G.M.; Humphreys, T.M.; Ketteler, H.J.; Sullivan, C.K.; Taylor, V.L.; Schmidt, C.J. Characterization of the 5- HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: Behavioral, electrophysiological and neurochemical studies. J. Pharmacol. Exp. Ther., 1993, 266(2), 684-691. (Pubitemid 23318678)
233. Varty, G.B.; Bakshi, V.P.; Geyer, M.A. M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. Neuropsychopharmacol., 1999, 20(4), 311-321. (Pubitemid 29099762)
234. Kehne, J.H.; Ketteler, H.J.; McCloskey, T.C.; Sullivan, C.K.; Dudley, M.W.; Schmidt, C.J. Effects of the selective 5-HT2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats. Neuropsychopharmacology, 1996, 15(2), 116-124. (Pubitemid 26255158)
235. Grunder, G.; Yokoi, F.; Offord, S.J.; Ravert, H.T.; Dannals, R.F.; Salzmann, J.K.; Szymanski, S.; Wilson, P.D.; Howard, D.R.; Wong, D.F. Time course of 5-HT2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography. Neuropsychopharmacology, 1997, 17(3), 175-185. (Pubitemid 27365958)
236. Talvik-Lotfi, M.; Nyberg, S.; Nordstrom, A.-L.; Ito, H.; Halldin, C.; Brunner, F.; Farde, L. High 5HT2A receptor occupancy in M100907-treated schizophrenic patients. Psychopharmacology, 2000, 148(4), 400-403. (Pubitemid 30169758)
237. Offord, S.J. M100907, a highly selective 5-HT2A antagonist for the treatment of schizophrenia: Early indication of safety and clinical activity in schizophrenic patients. CINP Proc., 1998, PT10052, 377.
238. Bartoszyk, G.D.; Van Amsterdam, C.; Boettcher, H.; Seyfried, C.A. EMD 281014, a new selective serotonin 5-HT2A receptor antagonist. Eur. J. Pharmacol., 2003, 473(2-3), 229-230. (Pubitemid 36929889)
239. Mamo, D.; Sedman, E.; Tillner, J.; Sellers, E.M.; Romach, M.K.; Kapur, S. EMD 281014, a specific and potent 5HT2 antagonist in humans: A dosefinding PET study. Psychopharmacology, 2004, 175(3), 382-388. (Pubitemid 39361927)
240. Dray, A.; Gonye, T.J.; Oakley, N.R.; Tanner, T. Evidence for the existence of a raphe projection to the substantia nigra in rat. Brain Res., 1976, 113(1), 45-57.
241. Herve, D.; Pickel, V.M.; Joh, T.H.; Beaudet, A. Serotonin axon terminals in the ventral tegmental area of the rat: Fine structure and synaptic input to dopaminergic neurons. Brain Res., 1987, 435(1-2), 71-83. (Pubitemid 18009774)
242. van der Kooy, D.; Hattori, T. Dorsal raphe cells with collateral projections to the caudate-putamen and substantia nigra: A fluorescent retrograde double labeling study in the rat. Brain Res., 1980, 186(1), 1-7. (Pubitemid 10131856)
243. Imai, H.; Steindler, D.A.; Kitai, S.T. The organization of divergent axonal projections from the midbrain raphe nuclei in the rat. J. Comp. Neurol., 1986, 243(3), 363-380. (Pubitemid 16179241)
244. Lavoie, B.; Parent, A. Immunohistochemical study of the serotoninergic innervation of the basal ganglia in the squirrel monkey. J. Comp. Neurol., 1990, 299(1), 1-16. (Pubitemid 20311021)
245. Steinbusch, H.W.M. Distribution of serotonin-immunoreactivity in the central nervous system of the rat- cell bodies and terminals. Neuroscience, 1981, 6(4), 557-618. (Pubitemid 11102583)
246. Ichikawa, J.; Meltzer, H.Y. DOI, a 5-HT2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat striatum. Brain Res., 1995, 698(1,2), 204-208.
247. Lucas, G.; Spampinato, U. Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. J. Neurochem., 2000, 74(2), 693-701. (Pubitemid 30053742)
248. Schmidt, C.J.; Sullivan, C.K.; Fadayel, G.M. Blockade of striatal 5- hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analog 3,4- methylenedioxymethamphetamine. J. Neurochem., 1994, 62(4), 1382-1389.
249. Bowers, B.J.; Henry, M.B.; Thielen, R.J.; McBride, W.J. Serotonin 5-HT2 receptor stimulation of dopamine release in the posterior but not anterior nucleus accumbens of the rat. J. Neurochem., 2000, 75(4), 1625-1633.
250. Parsons, L.H.; Justice, J.B., Jr. Perfusate serotonin increases extracellular dopamine in the nucleus accumbens as measured by in vivo microdialysis. Brain Res., 1993, 606(2), 195-199. (Pubitemid 23098366)
251. Alex, K.D.; Pehek, E.A. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol. Ther., 2007, 113(2), 296-320. (Pubitemid 46149046)
252. Gobert, A.; Millan, M.J. Serotonin (5-HT)2A receptor activation enhances dialyzate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats. Neuropharmacology, 1999, 38(2), 315-317. (Pubitemid 29073553)
253. Pehek, E.A.; McFarlane, H.G.; Maguschak, K.; Price, B.; Pluto, C.P. M- 100907, a selective 5-HT2A antagonist, attenuates dopamine release in the rat medial prefrontal cortex. Brain Res., 2001, 888(1), 51-59. (Pubitemid 32056261)
254. Casey, D.E. Pathophysiology of antipsychotic drug-induced movement disorders. J. Clin. Psychiatry, 2004, 65 Suppl 9, 25-28.
255. Ceskova, E.; Svestka, J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry, 1993, 26(4), 121-124.
256. Perregaard, J.; Arnt, J.; Boegesoe, K.P.; Hyttel, J.; Sanchez, C. Noncataleptogenic, centrally acting dopamine D-2 and serotonin 5-HT2 antagonists within a series of 3-substituted 1-(4-fluorophenyl)-1H-indoles. J. Med. Chem., 1992, 35(6), 1092-1101.
257. Andersen, K.; Perregaard, J.; Arnt, J.; Nielsen, J.B.; Begtrup, M. Selective, centrally acting serotonin 5-HT2 antagonists. 2. Substituted 3-(4- fluorophenyl)-1H-indoles. J. Med. Chem., 1992, 35(26), 4823-4831. (Pubitemid 23030917)
258. Domeney, A.M.; Arnt, J.; Costall, B.; Naylor, R.J.; Sanchez, C.; Smith, A.G. Effect of sertindole on raised mesolimbic dopaminergic activity in the rat. Drug Develop. Res., 1994, 31(3), 175-185. (Pubitemid 24232577)
259. Kane, J.M. Sertindole: A review of clinical efficacy. Int. Clin. Psychopharmacol., 1998, 13 Suppl 3, S59-63; discussion S63-54.
260. Tamminga, C.A.; Mack, R.J.; Granneman, G.R.; Silber, C.J.; Kashkin, K.B. Sertindole in the treatment of psychosis in schizophrenia: Efficacy and safety. Int. Clin. Psychopharmacol., 1997, 12 Suppl 1, S29-35. (Pubitemid 27171186)
261. van Kammen, D.P.; McEvoy, J.P.; Targum, S.D.; Kardatzke, D.; Sebree, T.B. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology, 1996, 124(1/2), 168-175. (Pubitemid 26112786)
262. Seeger, T.F.; Seymour, P.A.; Schmidt, A.W.; Zorn, S.H.; Schulz, D.W.; Lebel, L.A.; McLean, S.; Guanowsky, V.; Howard, H.R.; Lowe, J.A. III.; Heym, J. Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J. Pharmacol. Exp. Ther., 1995, 275(1), 101-113.
263. Keck, P., Jr.; Buffenstein, A.; Ferguson, J.; Feighner, J.; Jaffe, W.; Harrigan, E.P.; Morrissey, M.R. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial. Psychopharmacology, 1998, 140(2), 173-184. (Pubitemid 28538477)
264. Lee, T.; Robichaud, A.J.; Boyle, K.E.; Lu, Y.; Robertson, D.W.; Miller, K.J.; Fitzgerald, L.W.; McElroy, J.F.; Largent, B.L. Novel, highly potent, selective 5-HT2A/D2 receptor antagonists as potential atypical antipsychotics. Bioorg. Med. Chem. Lett., 2003, 13(4), 767-770. (Pubitemid 36298487)
265. Malleron, J.L.; Comte, M.T.; Gueremy, C.; Peyronel, J.F.; Truchon, A.; Blanchard, J.C.; Doble, A.; Piot, O.; Zundel, J.L.; Huon, C.; Martin, B.; Mouton, P.; Viroulaud, A.; Allam, D.; Betschart, J.Naphthosultam derivatives: A new class of potent and selective 5-HT2 antagonists. J. Med. Chem., 1991, 34(8), 2477-2483.
266. Doble, A.; Girdlestone, D.; Piot, O.; Allam, D.; Betschart, J.; Boireau, A.; Dupuy, A.; Gueremy, C.; Menager, J.; Zundel, J.L. Pharmacological characterization of RP 62203, a novel 5-hydroxytryptamine 5-HT2 receptor antagonist. Br. J. Pharmacol., 1992, 105(1), 27-36.
267. Heuillet, E.; Petitet, F.; Mignani, S.; Malleron, J.-L.; Lavayre, J.; Neliat, G.; Doble, A.; Blanchard, J.-C. The naphthosultam derivative RP 62203 (fananserin) has high affinity for the dopamine D4 receptor. Eur. J. Pharmacol., 1996, 314(1/2), 229-233. (Pubitemid 26378907)
268. Sramek, J.J.; Kirkesseli, S.; Paccaly-Moulin, A.; Davidson, J.; Jhee, S.S.; Hourani, J.; Semiond, D.; Cutler, N.R. A bridging study of fananserin in schizophrenic patients. Psychopharmacol. Bull., 1998, 34(4), 811-818. (Pubitemid 29497930)
269. Liegeois, J.F.F.; Rogister, F.A.; Bruhwyler, J.; Damas, J.; Nguyen, T.P.; Inarejos, M.O.; Chleide, E.M.G.; Mercier, M.G.A.; Delarge, J.E. Pyridobenzoxazepine and pyridobenzothiazepine derivatives as potential central nervous system agents: Synthesis and neurochemical study. J. Med. Chem., 1994, 37(4), 519-525. (Pubitemid 24094833)
270. Bruhwyler, J.; Liegeois, J.-F.; Bergman, J.; Carey, G.; Goudie, A.; Taylor, A.; Meltzer, H.; Delarge, J.; Geczy, J. JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: A review of its behavioral properties. Pharmacol. Res., 1997, 36(4), 255-264. (Pubitemid 27507581)
271. Casey, D.E.; Bruhwyler, J.; Delarge, J.; Geczy, J.; Liegeois, J.-F. The behavioral effects of acute and chronic JL 13, an putative antipsychotic, in Cebus non-human primates. Psychopharmacology, 2001, 157(3), 228-235. (Pubitemid 32905563)
272. Ellenbroek, B.A.; Liegeois, J.-F.; Bruhwyler, J.; Cools, A.R. Effects of JL13, a pyridobenzoxazepine with potential atypical antipsychotic activity, in animal models for schizophrenia. J. Pharmacol. Exp. Ther., 2001, 298(1), 386-391. (Pubitemid 32574551)
273. Liegeois, J.F.; Zahid, N.; Bruhwyler, J.; Uetrecht, J. Hypochlorous acid, a major oxidant produced by activated neutrophils, has low effect on two pyridobenzazepine derivatives, JL 3 and JL 13. Arch. Pharm., 2000, 333(2- 3), 63-67. (Pubitemid 30211871)
274. Liegeois, J.-F.; Mouithys-Mickalad, A.; Bruhwyler, J.; Delarge, J.; Petit, C.; Kauffmann, J.-M.; Lamy, M. JL 13, a potential successor to clozapine, is less sensitive to oxidative phenomena. Biochem. Bioph. Res. Co., 1997, 238(1), 252-255. (Pubitemid 27453310)
275. Steiner, G.; Bach, A.; Bialojan, S.; Greger, G.; Hoeger, T.; Klebe, G.; Munschauer, R.; Teschendorf, H.-J.; Traut, M.; Unger, L. LU 111995: A novel D4 / 5-HT2 receptor antagonist and potential new antipsychotic. In Book of Abstracts, 213th ACS National Meeting, San Francisco, April 13-17, 1997; pp MEDI-186.
276. Geyer, M.A.; Swerdlow, N.R.; Lehmann-Masten, V.; Teschendorf, H.-J.; Traut, M.; Gross, G. Effects of LU-111995 in three models of disrupted prepulse inhibition in rats. J. Pharmacol. Exp. Ther., 1999, 290(2), 716-724. (Pubitemid 29344567)
277. Steiner, G.; Bach, A.; Bialojan, S.; Greger, G.; Hege, H.-G.; Hoger, T.; Jochims, K.; Munschauer, R.; Neumann, B.; Teschendorf, H.-J.; Traut, M.; Unger, L.; Gross, G. D4/5-HT2A receptor antagonists: LU-111995 and other potential new antipsychotics in development. Drug Future, 1998, 23(2), 191-204. (Pubitemid 28191591)
278. Okuyama, S.; Chaki, S.; Yoshikawa, R.; Suzuki, Y.; Ogawa, S.-I.; Imagawa, Y.; Kawashima, N.; Ikeda, Y.; Kumagai, T.; Nakazato, A.; Nagamine, M.; Tomisawa, K. In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5- [1- [4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin- 3-yl]thiazole (NRA0045). J. Pharmacol. Exp. Ther., 1997, 282(1), 56-63. (Pubitemid 27425526)
279. Okuyama, S.; Chaki, S.; Kawashima, N.; Suzuki, Y.; Ogawa, S.-I.; Kumagai, T.; Nakazato, A.; Nagamine, M.; Yamaguchi, K.; Tomisawa, K. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5- hydroxytryptamine2A receptor antagonist, in rats. Br. J. Pharmacol., 1997, 121(3), 515-525. (Pubitemid 27226305)
280. Chaki, S.; Funakoshi, T.; Yoshikawa, R.; Okuyama, S.; Kumagai, T.; Nakazato, A.; Nagamine, M.; Tomisawa, K. In vivo receptor occupancy of NRA0045, a putative atypical antipsychotic, in rats. Neuropharmacology, 1999, 38(8), 1185-1194. (Pubitemid 29292407)
281. Levenson, J.L. Neuroleptic malignant syndrome. Am. J. Psychiatry, 1985, 142(10), 1137-1145. (Pubitemid 16223648)
282. Holstein, A.P.; Chen, C.H. Haloperidol-A preliminary clinical study. Am. J. Psychiatry., 1965, 122(4), 462-463.
283. King, D.J. Drug treatment of the negative symptoms of schizophrenia. Eur. Neuropsychopharm., 1998, 8(1), 33-42. (Pubitemid 28012858)
284. Palao, D.J.; Arauxo, A.; Brunet, M.; Marquez, M.; Bernardo, M.; Ferrer, J.; Gonzalez-Monclus, E. Positive versus negative symptoms in schizophrenia: Response to haloperidol. Prog. Neuropsychopharmacol. Biol. Psychiatry, 1994, 18(1), 155-164.
285. Bobba, R. Severe extrapyramidal side effects when discontinuing clozapine and starting haloperidol. Can. J. Psychiatry, 1997, 42(5), 530. (Pubitemid 27298740)
286. Kurz, M.; Hummer, M.; Oberbauer, H.; Fleischhacker, W.W. Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology, 1995, 118(1), 52-56.
287. Moleman, P.; Schmitz, P.J.; Ladee, G.A. Extrapyramidal side effects and oral haloperidol: An analysis of explanatory patient and treatment characteristics. J. Clin. Psychiatry, 1982, 43(12), 492-496. (Pubitemid 13217714)
288. Broich, K.; Grunwald, F.; Kasper, S.; Klemm, E.; Biersack, H.J.; Moller, H.J. D2-dopamine receptor occupancy measured by IBZM-SPECT in relation to extrapyramidal side effects. Pharmacopsychiatry, 1998, 31(5), 159-162. (Pubitemid 28505906)
289. Knable, M.B.; Weinberger, D.R. Dopamine, the prefrontal cortex and schizophrenia. J. Psychopharmacol., 1997, 11(2), 123-131.
290. Beasley, C.M.; Dellva, M.A.; Tamura, R.N.; Morgenstern, H.; Glazer, W.M.; Ferguson, K.; Tollefson, G.D. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during longterm treatment with olanzapine or haloperidol. Br. J. Psychiatry., 1999, 174, 23-30. (Pubitemid 29037880)
291. Gunne, L.M.; Barany, S. Haloperidol-induced tardive dyskinesia in monkeys. Psychopharmacology, 1976, 50(3), 237-240.
292. Petty, L.K.; Spar, C.J. Haloperidol-induced tardive dyskinesia in a 10-yearold girl. Am. J. Psychiatry, 1980, 137(6), 745-746. (Pubitemid 10121016)
293. Richardson, M.A.; Haugland, G.; Craig, T.J. Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients. Am. J. Psychiatry, 1991, 148(10), 1322-1328.
294. Lischke, V.; Behne, M.; Doelken, P.; Schledt, U.; Probst, S.; Vettermann, J. Droperidol causes a dose-dependent prolongation of the QT interval. Anesth. Analg., 1994, 79(5), 983-986. (Pubitemid 24324682)
295. Kumar, A.; Strech, D. Zuclopenthixol dihydrochloride for schizophrenia. Cochrane Database Syst. Rev., 2005, (4), CD005474.
296. Quraishi, S.; David, A. Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders. Cochrane Database Syst. Rev., 2000, (2), CD001470.
297. Hekimian, L.J.; Gershon, S.; Floyd, A., Jr. Some clinical and physiologic effects of a thioxanthene derivative, thiothixene (P-4657B), in 20 newly hospitalized male schizophrenics. J. Clin. Pharmacol. J. New Drugs, 1967, 7(1), 52-57.
298. Bente, D.; Engelmeier, M.P.; Heinrich, K.; Hippius, H.; Schmitt, W. Clinical studies with a neuroleptically active dibenzothiazepine derivative. Arznei- Forschung, 1966, 16(2), 314-316.
299. Gross, H.; Langner, E. Effect profile of a chemically new broad spectrum neuroleptic of the dibenzo-diazepine group. Wien. Med. Wochenschr., 1966, 116(40), 814-816.
300. Angst, J.; Jaenicke, U.; Padrutt, A.; Scharfetter, C. Double blind study with HF 1854 (8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo [b,e] [1,4] diazepine) in comparison with levomepromazine. Pharmakopsych. Neuro., 1971, 4(4), 192-200.
301. Ionescu, R.; Nica, S.U.; Oproiu, L.; Niturad, A.; Tudorache, B. Double-blind study in psychopathic behavior disorders (clozapine and pericyazine). Pharmakopsych. Neuro., 1973, 6(6), 294-299.
302. Zapletalek, M.; Pazdirek, S.; Hubsch, T.; Strnad, D. Clinical experience with clozapine in psychoses. Act. Nerv. Super., 1974, 16(3), 203-204.
303. Farde, L.; Wiesel, F.A.; Nordstroem, A.L.; Sedvall, G. D1- And D2- dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology, 1989, 99(Suppl.), S28-S31. (Pubitemid 19244135)
304. Lahti, R.A.; Evans, D.L.; Stratman, N.C.; Figur, L.M. Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: Possible therapeutic implications. Eur. J. Pharmacol., 1993, 236(3), 483-486. (Pubitemid 23170391)
305. Wilson, J.M.; Sanya, S.; Van Tol, H.H.M. Dopamine D2 and D4 receptor ligands: Relation to antipsychotic action. Eur. J. Pharmacol., 1998, 351(3), 273-286. (Pubitemid 28321462)
306. Breier, A.; Buchanan, R.W.; Kirkpatrick, B.; Davis, O.R.; Irish, D.; Summerfelt, A.; Carpenter, W.T., Jr. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am. J. Psychiat., 1994, 151(1), 20-26. (Pubitemid 24020107)
307. Lindenmayer, J.P.; Grochowski, S.; Mabugat, L. Clozapine effects on positive and negative symptoms: A six-month trial in treatment-refractory schizophrenics. J. Clin. Psychopharm., 1994, 14(3), 201-204. (Pubitemid 24182187)
308. Young, C.R.; Longhurst, J.G.; Bowers, M.B., Jr.; Mazure, C.M. The expanding indications for clozapine. Exp. Clin. Psychopharm., 1997, 5(3), 216-234. (Pubitemid 27346446)
309. Zink, M.; Dressing, H. Augmentation of clozapine with atypical antipsychotic substances. Curr. Psychiatr. Rev., 2005, 1(2), 165-172.
310. Sagar, S.M.; Sharp, F.R.; Curran, T. Expression of c-fos protein in brain: Metabolic mapping at the cellular level. Science, 1988, 240(4857), 1328-1331.
311. Fujimura, M.; Hashimoto, K.; Yamagami, K. The effect of the antipsychotic drug mosapramine on the expression of Fos protein in the rat brain: Comparison with haloperidol, clozapine and risperidone. Life Sci., 2000, 67(23), 2865-2872.
312. Deutch, A.Y.; Lee, M.C.; Iadarola, M.J. Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: The nucleus accumbens shell as a locus of antipsychotic action. Mol. Cell Neurosci., 1992, 3(4), 332-341.
313. Wirtshafter, D.; Asin, K.E. Effects of haloperidol and clozapine on Fos expression in the primate striatum. NeuroReport, 2003, 14(18), 2429-2432.
314. Spivak, B.; Mester, R.; Abesgaus, J.; Wittenberg, N.; Adlersberg, S.; Gonen, N.; Weizman, A. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J. Clin. Psychiat., 1997, 58(7), 318-322. (Pubitemid 27362488)
315. Casey, D.E. Clozapine: Neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology, 1989, 99 Suppl, S47-53. (Pubitemid 19244139)
316. Simpson, G.M.; Lee, J.H.; Shrivastava, R.K. Clozapine in tardive dyskinesia. Psychopharmacology, 1978, 56(1), 75-80. (Pubitemid 8270659)
317. Kane, J.M.; Woerner, M.G.; Pollack, S.; Safferman, A.Z.; Lieberman, J.A. Does clozapine cause tardive dyskinesia? J. Clin. Psychiatry., 1993, 54(9), 327-330. (Pubitemid 23322379)
318. Meltzer, H.Y.; Goode, D.J.; Schyve, P.M.; Young, M.; Fang, V.S. Effect of clozapine on human serum prolactin levels. Am. J. Psychiatry., 1979, 136(12), 1550-1555. (Pubitemid 10206621)
319. Kane, J.M.; Cooper, T.B.; Sachar, E.J.; Halpern, F.S.; Bailine, S. Clozapine: Plasma levels and prolactin response. Psychopharmacology, 1981, 73(2), 184-187. (Pubitemid 11150297)
320. Spivak, B.; Roitman, S.; Vered, Y.; Mester, R.; Graff, E.; Talmon, Y.; Guy, N.; Gonen, N.; Weizman, A. Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clin. Neuropharmacol., 1998, 21(4), 245-250. (Pubitemid 28367078)
321. Meltzer, H.Y.; Okayli, G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: Impact on risk-benefit assessment. Am. J. Psychiat., 1995, 152(2), 183-190.
322. Idanpaan-Heikkila, J.; Alhava, E.; Olkinuora, M.; Palva, I.P. Agranulocytosis during treatment with chlozapine. Eur. J. Clin. Pharmacol., 1977, 11(3), 193-198.
323. Idanpaan-Heikkila, J.; Alhava, E.; Olkinuora, M.; Palva, I. Letter: Clozapine and agranulocytosis. Lancet, 1975, 2(7935), 611.
324. Alvir, J.M.; Lieberman, J.A.; Safferman, A.Z.; Schwimmer, J.L.; Schaaf, J.A. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N. Engl. J. Med., 1993, 329(3), 162-167. (Pubitemid 23195736)
325. Meltzer, H.Y. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr. Bull., 1992, 18(3), 515-542.
326. Kane, J.; Honigfeld, G.; Singer, J.; Meltzer, H. Clozapine for the treatmentresistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry, 1988, 45(9), 789-796.
327. Cohen, S.; Chiles, J.; MacNaughton, A. Weight gain associated with clozapine. Am. J. Psychiat., 1990, 147(4), 503-504. (Pubitemid 20107121)
328. Theisen, F.M.; Cichon, S.; Linden, A.; Martin, M.; Remschmidt, H.; Hebebrand, J. Clozapine and weight gain. Am. J. Psychiat., 2001, 158(5), 816.
329. Popli, A.P.; Konicki, P.E.; Jurjus, G.J.; Fuller, M.A.; Jaskiw, G.E. Clozapine and associated diabetes mellitus. J. Clin. Psychiat., 1997, 58(3), 108-111. (Pubitemid 27149251)
330. Henderson, D.C. Clozapine: Diabetes mellitus, weight gain, and lipid abnormalities. J. Clin. Psychiat., 2001, 62(Suppl. 23), 39-44. (Pubitemid 32952693)
331. Newcomer, J.W. Antipsychotic medication-induced weight gain and risk for diabetes and cardiovascular disease. In Energy Metabolism and Obesity, Humana Press: New Jersey, 2008; pp 223-245.
332. Schotte, A.; Janssen, P.F.M.; Megens, A.A.H.P.; Leysen, J.E. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res., 1993, 631(2), 191-202. (Pubitemid 24009988)
333. Carman, J.; Peuskens, J.; Vangeneugden, A. Risperidone in the treatment of negative symptoms of schizophrenia: A meta-analysis. Int. Clin. Psychopharmacol., 1995, 10(4), 207-213.
334. Marder, S.R.; Davis, J.M.; Chouinard, G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials. J. Clin. Psychiatry, 1997, 58(12), 538-546. (Pubitemid 28100274)
335. Chouinard, G.; Jones, B.; Remington, G.; Bloom, D.; Addington, D.; MacEwan, G.W.; Labelle, A.; Beauclair, L.; Arnott, W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychopharm., 1993, 13(1), 25-40. (Pubitemid 23030357)
336. Miller, C.H.; Mohr, F.; Umbricht, D.; Woerner, M.; Fleischhacker, W.W.; Lieberman, J.A. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J. Clin. Psychiatry, 1998, 59(2), 69-75. (Pubitemid 28141238)
337. Leucht, S.; Pitschel-Walz, G.; Abraham, D.; Kissling, W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr. Res., 1999, 35(1), 51-68. (Pubitemid 29023554)
338. Knable, M.B.; Heinz, A.; Raedler, T.; Weinberger, D.R. Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. Psychiatry Res., 1997, 75(2), 91-101. (Pubitemid 27435975)
339. Marder, S.R.; Meibach, R.C. Risperidone in the treatment of schizophrenia. Am. J. Psychiat., 1994, 151(6), 825-835.
340. Peuskens, J. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br. J. Psychiat., 1995, 166(6), 712-726; discussion 727-733.
341. Csernansky John, G.; Mahmoud, R.; Brenner, R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med., 2002, 346(1), 16-22. (Pubitemid 34438915)
342. Kleinberg, D.L.; Davis, J.M.; De Coster, R.; Van Baelen, B.; Brecher, M. Prolactin levels and adverse events in patients treated with risperidone. J. Clin. Psychopharm., 1999, 19(1), 57-61. (Pubitemid 29047332)
343. Mesotten, F.; Suy, E.; Pietquin, M.; Burton, P.; Heylen, S.; Gelders, Y. Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients. Psychopharmacology, 1989, 99(4), 445-449. (Pubitemid 19273097)
344. Hasan, S.; Buckley, P. Novel antipsychotics and the neuroleptic malignant syndrome: A review and critique. Am. J. Psychiat., 1998, 155(8), 1113-1116. (Pubitemid 28357742)
345. Drolet, B.; Yang, T.; Daleau, P.; Roden, D.M.; Turgeon, J. Risperidone Prolongs Cardiac Repolarization by Blocking the Rapid Component of the Delayed Rectifier Potassium Current. J. Cardiovasc. Pharm., 2003, 41(6), 934-937. (Pubitemid 36706143)
346. Bymaster, F.P.; Nelson, D.L.; DeLapp, N.W.; Falcone, J.F.; Eckols, K.; Truex, L.L.; Foreman, M.M.; Lucaites, V.L.; Calligaro, D.O. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr. Res., 1999, 37(1), 107-122. (Pubitemid 29167031)
347. Richelson, E. Preclinical pharmacology of neuroleptics: Focus on new generation compounds. J. Clin. Psychiatry, 1996, 57(Suppl. 11), 4-11.
348. Beasley, C.M. Efficacy of olanzapine: An overview of pivotal clinical trials. J. Clin. Psychiatry, 1997, 58(2), 16-18.
349. Tollefson, G.D.; Beasley, C.M., Jr.; Tran, P.V.; Street, J.S.; Krueger, J.A.; Tamura, R.N.; Graffeo, K.A.; Thieme, M.E. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am. J. Psychiatry, 1997, 154(4), 457-465. (Pubitemid 27147597)
350. Tran, P.V.; Dellva, M.A.; Tollefson, G.D.; Beasley, C.M., Jr.; Potvin, J.H.; Kiesler, G.M. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J. Clin. Psychiatry, 1997, 58(5), 205-211. (Pubitemid 27242007)
351. Steinwachs, A.; Grohmann, R.; Pedrosa, F.; Ruther, E.; Schwerdtner, I. Two cases of olanzapine-induced reversible neutropenia. Pharmacopsychiatry, 1999, 32(4), 154-156. (Pubitemid 29434282)
352. Benedetti, F.; Cavallaro, R.; Smeraldi, E. Olanzapine-induced neutropenia after clozapine-induced neutropenia. Lancet, 1999, 354(9178), 567. (Pubitemid 29381376)
353. Tchernichovsky, E.; Sirota, P. Hepatotoxicity, leucopenia and neutropenia associated with olanzapine therapy. Int. J. Psychiat. Clin., 2004, 8(3), 173-177. (Pubitemid 39382089)
354. Burkhard, P.R.; Vingerhoets, F.J.; Alberque, C.; Landis, T. Olanzapineinduced neuroleptic malignant syndrome. Arch. Gen. Psychiatry, 1999, 56(1), 101-102.
355. Beasley, C.M., Jr.; Tollefson, G.D.; Tran, P.V. Safety of olanzapine. J. Clin. Psychiatry, 1997, 58(Suppl. 10), 13-17. (Pubitemid 27333175)
356. Bonanno, D.G.; Davydov, L.; Botts, S.R. Olanzapine-induced diabetes mellitus. Ann. Pharmacother., 2001, 35(5), 563-565. (Pubitemid 32428131)
357. Farwell Wildon, R.; Stump Timothy, E.; Wang, J.; Tafesse, E.; L'Italien, G.; Tierney William, M. Weight gain and new onset diabetes associated with olanzapine and risperidone. J. Gen. Intern. Med., 2004, 19(12), 1200-1205. (Pubitemid 40041384)
358. Saller, C.F.; Salama, A.I. Seroquel: Biochemical profile of a potential atypical antipsychotic. Psychopharmacology, 1993, 112(2-3), 285-292. (Pubitemid 23278291)
359. Sirota, P.; Pannet, I.; Koren, A.; Tchernichovsky, E. Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia. Hum. Psychopharmacol., 2006, 21(4), 227-234. (Pubitemid 44054863)
360. Zhong, K.X.; Sweitzer, D.E.; Hamer, R.M.; Lieberman, J.A. Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. J. Clin. Psychiat., 2006, 67(7), 1093-1103. (Pubitemid 44230881)
361. Buckley, P.F. Efficacy of quetiapine for the treatment of schizophrenia: A combined analysis of three placebo-controlled trials. Curr. Med. Res. Opin., 2004, 20(9), 1357-1363. (Pubitemid 39361338)
362. Misra, L.K.; Erpenbach, J.E.; Hamlyn, H.; Fuller, W.C. Quetiapine: A new atypical antipsychotic. S D J. Med., 1998, 51(6), 189-193.
363. Barnes, T.R.; McPhillips, M.A. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia. Int. Clin. Psychopharmacol., 1998, 13 Suppl 3, S49-57. (Pubitemid 28282871)
364. Small, J.G.; Hirsch, S.R.; Arvantis, L.A.; Miller, B.G.; Link, C.G.G. Quetiapine in patients with schizophrenia. A high- And low-dose doubleblind comparison with placebo. Arch. Gen. Psychiatry, 1997, 54(6), 549-557. (Pubitemid 27258553)
365. Peuskens, J.; Link, C.G.G. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiat. Scand., 1997, 96(4), 265-273. (Pubitemid 27428238)
366. Kasper, S.; Muller-Spahn, F. Review of quetiapine and its clinical applications in schizophrenia. Expert Opin. Pharmacol., 2000, 1(4), 783-801.
367. Schmidt, A.W.; Lebel, L.A.; Howard, H.R.; Zorn, S.H. Ziprasidone: A novel antipsychotic agent with a unique human receptor binding profile. Eur. J. Pharmacol., 2001, 425(3), 197-201. (Pubitemid 32770067)
368. Stahl, S.M.; Shayegan, D.K. The psychopharmacology of ziprasidone: Receptor-binding properties and real-world psychiatric practice. J. Clin. Psychiatry, 2003, 64(Suppl. 19), 6-12.
369. Allison, D.B.; Mentore, J.L.; Heo, M.; Chandler, L.P.; Cappelleri, J.C.; Infante, M.C.; Weiden, P.J. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am. J. Psychiatry, 1999, 156(11), 1686-1696. (Pubitemid 29517559)
370. Daniel, D.G.; Zimbroff, D.L.; Potkin, S.G.; Reeves, K.R.; Harrigan, E.P.; Lakshminarayanan, M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial. Neuropsychopharmacology, 1999, 20(5), 491-505. (Pubitemid 29123876)
371. Arato, M.; O'Connor, R.; Meltzer, H.Y. A 1-year, double-blind, placebocontrolled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: The Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int. Clin. Psychopharmacol., 2002, 17(5), 207-215.
372. Burton, S.; Heslop, K.; Harrison, K.; Barnes, M. Ziprasidone overdose. Am. J. Psychiatry, 2000, 157(5), 835.
373. House, M. Overdose of ziprasidone. Am. J. Psychiatry, 2002, 159(6), 1061-1062.
374. Taylor, D. Ziprasidone in the management of schizophrenia: The QT interval issue in context. CNS Drugs, 2003, 17(6), 423-430. (Pubitemid 36560704)
375. Kane, J.M.; Carson, W.H.; Saha, A.R.; McQuade, R.D.; Ingenito, G.G.; Zimbroff, D.L.; Ali, M.W. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry, 2002, 63(9), 763-771.
376. de Leon, A.; Patel, N.C.; Crismon, M.L. Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin. Ther., 2004, 26(5), 649-666. (Pubitemid 38736956)
377. Witschy James, K.; Winter, A.S. Improvement in tardive dyskinesia with aripiprazole use. Can. J. Psychiatry, 2005, 50(3), 188. (Pubitemid 40515979)
378. Miller, D.D.; Eudicone, J.M.; Pikalov, A.; Kim, E. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: A post hoc analysis. J. Clin. Psychiatry, 2007, 68(12), 1901-1906.
379. Madhusoodanan, S.; Brenner, R.; Gupta, S.; Reddy, H.; Bogunovic, O. Clinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: Retrospective case studies. CNS Spectr., 2004, 9(11), 862-867. (Pubitemid 39602941)
380. Hammerman, S.; Lam, C.; Caroff Stanley, N. Neuroleptic malignant syndrome and aripiprazole. J. Am. Acad. Child Psy., 2006, 45(6), 639-641.
381. Chakraborty, N.; Johnston, T. Aripiprazole and neuroleptic malignant syndrome. Int. Clin. Psychopharmacol., 2004, 19(6), 351-353. (Pubitemid 39506991)
382. Hogberg, T.; Ramsby, S.; Ogren, S.O.; Norinder, U. New selective dopamine D-2 antagonists as antipsychotic agents. Pharmacological, chemical, structural and theoretical considerations. Acta Pharm. Suec., 1987, 24(6), 289-328. (Pubitemid 18091474)
383. Mielke, D.H.; Gallant, D.M.; Roniger, J.J.; Kessler, C. Sulpiride: Evaluation of antipsychotic activity in chronic schizophrenic patients. Psychopharmacol. Bull., 1977, 13(3), 40-41.
384. Scatton, B.; Claustre, Y.; Cudennec, A.; Oblin, A.; Perrault, G.; Sanger, D.J.; Schoemaker, H. Amisulpride: From animal pharmacology to therapeutic action. Int. Clin. Psychopharmacol., 1997, 12 Suppl 2, S29-36. (Pubitemid 27286568)
385. Danion, J.M.; Rein, W.; Fleurot, O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am. J. Psychiat., 1999, 156(4), 610-616. (Pubitemid 29162984)
386. Perrault, G.; Depoortere, R.; Morel, E.; Sanger, D.J.; Scatton, B. Psychopharmacological profile of amisulpride: An antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J. Pharmacol. Exp. Ther., 1997, 280(1), 73-82. (Pubitemid 27171390)
387. Schoemaker, H.; Claustre, Y.; Fage, D.; Rouquier, L.; Chergui, K.; Curet, O.; Oblin, A.; Gonon, F.; Carter, C.; Benavides, J.; Scatton, B. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J. Pharmacol. Exp. Ther., 1997, 280(1), 83-97. (Pubitemid 27171391)
388. Wetzel, H.; Grunder, G.; Hillert, A.; Philipp, M.; Gattaz, W.F.; Sauer, H.; Adler, G.; Schroder, J.; Rein, W.; Benkert, O.; The Amisulpride Study, G. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology- A double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. Psychopharmacology, 1998, 137(3), 223-232. (Pubitemid 28277507)
389. Colonna, L.; Saleem, P.; Dondey-Nouvel, L.; Rein, W. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int. Clin. Psychopharmacol., 2000, 15(1), 13-22. (Pubitemid 30058134)
390. Moller, H.J.; Boyer, P.; Fleurot, O.; Rein, W. Improvement of acute exacerbations of schizophrenia with amisulpride: A comparison with haloperidol. Psychopharmacology, 1997, 132(4), 396-401. (Pubitemid 27373482)
391. Puech, A.; Fleurot, O.; Rein, W.; Amisulpride Study, G. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: A dose-ranging study vs. haloperidol. Acta Psychiat. Scand., 1998, 98(1), 65-72. (Pubitemid 28289460)
392. Peuskens, J.; Bech, P.; Moller, H.-J.; Bale, R.; Fleurot, O.; Rein, W. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Res., 1999, 88(2), 107-117. (Pubitemid 29507525)
393. Boyer, P.; Lecrubier, Y.; Puech, A.J.; Dewailly, J.; Aubin, F. Treatment of negative symptoms in schizophrenia with amisulpride. Br. J. Psychiat., 1995, 166(1), 68-72.
394. Loo, H.; Poirier-Littre, M.F.; Theron, M.; Rein, W.; Fleurot, O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br. J. Psychiatry, 1997, 170, 18-22. (Pubitemid 27404772)
395. Delcker, A.; Schoon, M.L.; Oczkowski, B.; Gaertner, H.J. Amisulpride versus haloperidol in treatment of schizophrenic patients-results of a doubleblind study. Pharmacopsychiatry, 1990, 23(3), 125-130. (Pubitemid 20304125)
396. Paparrigopoulos, T.; Liappas, J.; Tzavellas, E.; Mourikis, I.; Soldatos, C. Amisulpride-induced hyperprolactinemia is reversible following discontinuation. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31(1), 92-96. (Pubitemid 44959254)
397. Peretti, C.S.; Danion, J.M.; Kauffmann-Muller, F.; Grange, D.; Patat, A.; Rosenzweig, P. Effects of haloperidol and amisulpride on motor and cognitive skill learning in healthy volunteers. Psychopharmacology, 1997, 131(4), 329-338. (Pubitemid 27348698)
398. Heykants, J.; Huang, M.L.; Mannens, G.; Meuldermans, W.; Snoeck, E.; Van Beijsterveldt, L.; Van Peer, A.; Woestenborghs, R. The pharmacokinetics of risperidone in humans: A summary. J. Clin. Psychiatry, 1994, 55 Suppl, 13-17. (Pubitemid 24179364)
399. Schotte, A.; Bonaventure, P.; Janssen, P.F.M.; Leysen, J.E. In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: Risperidone compared with antipsychotics hitherto used. Jpn. J. Pharmacol., 1995, 69(4), 399-412. (Pubitemid 26013775)
400. Kane, J.; Canas, F.; Kramer, M.; Ford, L.; Gassmann-Mayer, C.; Lim, P.; Eerdekens, M. Treatment of schizophrenia with paliperidone extendedrelease tablets: A 6-week placebo-controlled trial. Schizophr. Res., 2007, 90(1-3), 147-161. (Pubitemid 46178537)
401. Davidson, M.; Emsley, R.; Kramer, M.; Ford, L.; Pan, G.; Lim, P.; Eerdekens, M. Efficacy, safety and early response of paliperidone extendedrelease tablets (paliperidone ER): Results of a 6-week, randomized, placebocontrolled study. Schizophr. Res., 2007, 93(1-3), 117-130. (Pubitemid 46817944)
402. Marder, S.R.; Kramer, M.; Ford, L.; Eerdekens, E.; Lim, P.; Eerdekens, M.; Lowy, A. Efficacy and safety of paliperidone extended-release tablets: Results of a 6-week, randomized, placebo-controlled study. Biol. Psychiatry, 2007, 62(12), 1363-1370. (Pubitemid 350180724)
403. Knegtering, R.; Baselmans, P.; Castelein, S.; Bosker, F.; Bruggeman, R.; van den Bosch Robert, J. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am. J. Psychiatry, 2005, 162(5), 1010-1012. (Pubitemid 40676220)
404. Kongsamut, S.; Roehr, J.E.; Cai, J.; Hartman, H.B.; Weissensee, P.; Kerman, L.L.; Tang, L.; Sandrasagra, A. Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur. J. Pharmacol., 1996, 317(2/3), 417-423. (Pubitemid 27014051)
405. Kalkman, H.O.; Subramanian, N.; Hoyer, D. Extended Radioligand Binding Profile of Iloperidone: A Broad Spectrum Dopamine/Serotonin/ Norepinephrine Receptor Antagonist for the Management of Psychotic Disorders. Neuropsychopharmacology, 2001, 25(6), 904-914. (Pubitemid 34031895)
406. Barr, A.M.; Powell, S.B.; Markou, A.; Geyer, M.A. Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats. Neuropharmacology, 2006, 51(3), 457-465. (Pubitemid 44215953)
407. Szewczak, M.R.; Corbett, R.; Rush, D.K.; Wilmot, C.A.; Conway, P.G.; Strupczewski, J.T.; Cornfeldt, M. The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. J. Pharmacol. Exp. Ther., 1995, 274(3), 1404-1413.
408. Corbett, R.; Hartman, H.; Kerman, L.L.; Woods, A.T.; Strupczewski, J.T.; Helsley, G.C.; Conway, P.C.; Dunn, R.W. Effects of atypical antipsychotic agents on social behavior in rodents. Pharmacol. Biochem. Behav., 1993, 45(1), 9-17.
409. Gemperle, A.Y.; McAllister, K.H.; Olpe, H.-R. Differential effects of iloperidone, clozapine, and haloperidol on working memory of rats in the delayed non-matching-to-position paradigm. Psychopharmacology, 2003, 169(3-4), 354-364. (Pubitemid 37255523)
410. Sainati, S.M.; Hubbard, J.W.; Chi, E.; Grasing, K.; Brecher, M.B. Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic. J. Clin. Pharmacol., 1995, 35(7), 713-720.
411. Weiden, P.J.; Cutler, A.J.; Polymeropoulos, M.H.; Wolfgang, C.D. Safety Profile of Iloperidone: A Pooled Analysis of 6-Week Acute-Phase Pivotal Trials. J. Clin. Psychopharm., 2008, 28(2, Suppl. 1), S12-S19. (Pubitemid 351397672)
412. Keppel Hesselink, J.M. Iloperidone (Novartis). IDrugs, 2002, 5(1), 84-90.
413. Shahid, M.; Walker, G.B.; Zorn, S.H.; Wong, E.H.F. Asenapine: A novel psychopharmacologic agent with a unique human receptor signature. J. Psychopharmacol., 2009, 23(1), 65-73.
414. Franberg, O.; Wiker, C.; Marcus, M.M.; Konradsson, A.; Jardemark, K.; Schilstroem, B.; Shahid, M.; Wong, E.H.F.; Svensson, T.H. Asenapine, a novel psychopharmacologic agent: Preclinical evidence for clinical effects in schizophrenia. Psychopharmacology, 2008, 196(3), 417-429. (Pubitemid 351200428)
415. Potkin, S.G.; Cohen, M.; Panagides, J. Efficacy and tolerability of asenapine in acute schizophrenia: A placebo- And risperidone-controlled trial. J. Clin. Psychiatry, 2007, 68(10), 1492-1500. (Pubitemid 350073395)